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ABSTRACT 
 
 
YUNFEI WANG: DOSE-FINDING DESIGNS FOR PHASE I CLINICAL TRIALS IN 
ONCOLOGY AND USE OF SELECTIVE PHENOTYPYING TO INCREASE POWER OF 
GENETIC ASSOCIATION STUDIES 
(Under the direction of Anastasia Ivanova & Ethan M. Lange) 
 
The goal of phase I clinical trials in oncology is to find a dose for a study that has 
acceptable toxicity or adverse effect associated with a pre-specified probability in patients 
experiencing DLT (dose limiting toxicity) for a drug. We propose a dose-finding design for Phase I 
oncology trials where each new patient is assigned to the dose most likely to be the target dose given 
observed data. The only assumption is that the dose-toxicity curve is non-decreasing. This method is 
especially beneficial when it is desirable to enroll patients into a study as soon as they present for the trial. 
To prevent assignments to doses with limited toxicity information in fast accruing trials we propose 
assigning temporary fractional toxicities to patients still in follow-up.  
The goal of a Phase I clinical trial in oncology is to find a dose with acceptable dose 
limiting toxicity rate. Often when a cytostatic drug is investigated or when the maximum 
tolerated dose is defined using a toxicity score, the main endpoint in a Phase I trial is continuous. 
We propose a new method to use in a dose-finding trial with continuous endpoints. The new 
method performs on par with other methods and provides more flexibility in assigning patients to 
doses in the course of the trial when the rate of accrual is fast relative to the follow-up time. 
 Blood-based biomarkers and other quantitative measures can provide valuable insights 
into disease etiology and are often used as intermediate outcomes for identifying risk factors 
associated with disease. Genome-wide association studies (GWAS) between quantitative traits 
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and single-nucleotide polymorphisms (SNPs) are routinely performed on large samples from 
population-based cohorts. Replication studies are an important step in controlling the type I error 
rate of reported GWAS findings. Many potential replication cohorts have existing genome-wide 
SNP data but have not yet measured the quantitative trait of interest.  Measuring these traits can 
be expensive and time consuming, which can deter studies from pursuing replication. Given the 
expense and time of measuring these quantitative traits on large samples, it would be desirable to 
identify a subset of subjects that could be phenotyped to optimize statistical power under fixed 
sample size constraints. We describe an approach of utilizing existing genotype data to identify 
an optimal subset of samples to be phenotyped and included in a genetic replication study.  
Specifically, we have developed a simulated annealing-based algorithm to optimally select 
samples to be phenotyped conditional on a list of candidate SNPs and available genotype data for 
those SNPs under a fixed sample size constraint. We demonstrate the increase in power of our 
approach relative to random sampling using simulations and a real replication study for C-
reactive protein levels. Our approach is flexible enough to allow constraints on available 
genotype counts and differential weighting of SNPs in the power calculations.   
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CHAPTER 1 
 
LITERATURE REVIEW 1: DOSE-FINDING DESIGNS IN PHASE I CLINICAL 
TRIALS IN ONCOLOGY 
 
1.1 Introduction 
The primary goal for Phase I oncology trials is to find the maximally tolerable dose 
(MTD), the dose with certain probability of dose limiting toxicity (DLT). One important 
assumption for dose-finding is that the toxicity for a new intervention increases monotonically 
with doses in Phase I clinical trials. The toxicity associated with a dose is so called dose limiting 
toxicity (DLT) which is often defined as treatment related non-hematological toxicity of grade 3 
or higher, or treatment related hematological toxicity of grade 4 or higher, where toxicity is 
measured on a scale from 0 to 5. 
In Phase I oncology clinical trials, there are some issues that need be taken into 
considerations: ethics, delayed onset of DLT, and continuous outcome. 
1)  The ethical issue is the reason that we seldom use healthy volunteers and that we 
should neither put many patients in those doses far above MTD, nor put many patients in those 
doses far below MTD when the patients consent to the study wishing to find cure by taking a 
new treatment. 
2)  Traditional designs are usually used to find MTD in the first cycle, however, delayed 
onset of toxicity can be observed beyond the first cycle. In traditional designs, admitting new 
patients into a trial requires that the current patients have completed follow-up to determine the 
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dose assigned to the new patients. For a traditional design, it takes a long time to finish when 
there is delayed onset of toxicity. Therefore traditional designs are not practical in clinical 
practice since doctors will not let patients waiting for treatment. 
3)  Another purpose of dose-finding in Phase I trials is to provide an efficacy dose of  
cytostatic agents  for the subsequent Phase II studies though to find a MTD is a primary goal for 
cytotoxic agents in Phase I trials. Continuous outcomes, such as measurement of target inhibition 
or pharmacokinetic endpoints such as plasma drug concentrations, are usually collected in such 
trials. The hypothesis that toxicity increases with increased dose is not necessary true for 
cytostatic agents. Toxicity may happen beyond the dose to yield sufficient efficacy. New drugs 
may incur only moderate toxicity with no DLT being observed.  Therefore, there is a need to turn 
the moderate toxicity into continuous scores and to find the dose targeting continuous outcome 
or scores. 
Our goal is to develop new approaches for dose-finding design in Phase I clinical trial for 
both binary and continuous outcomes with better operating characteristics without or with 
delayed onset toxicity. 
 
1.2 Designs or methods to solve the mentioned issues  
Designs for Phase I oncology trials can be categorized into two groups: non-parametric 
designs and parametric designs. In the following literature review section, we will describe these 
designs or methods in details. 
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1.2.1 Non-parametric designs  
In non-parametric designs, no prior assumption of dose-toxicity curve is stipulated with 
no parameters being estimated for dose escalation. Instead, dose allocation depends on the 
calculated statistics such as toxicity rate estimates or t statistics according to random walk rules 
or up-and-down rules. The principle of these rules is that the dose for the future cohort of 
patient(s) is decided based on the statistics of the observed data from the previous cohort of 
treated patient(s).  Traditional 3+3 design (Storer, 1989) which is a special form of A+B design 
(Lin and Shih, 2001), biased coin design (BCD) (Derman, 1957, Durham and Flournoy, 1994), 
group up-and-down design (Wetherill, 1963), moving average up-and-down design (Ivanova et 
al., 2003), group up-and-down design (Gezmu and Flournoy, 2006) are examples of non-
parametric design for dose finding trials. Some of these designs, such as BCD or group up-and-
down designs are Markov processes, and therefore their limiting distributions are easy to 
compute.  
Many non-parametric designs use isotonic regression to estimate dose toxicity curve. The 
only assumption is that the DLT rate is nondecreasing function of the dose.   These designs 
include isotonic design (Leung and Wang, 2001), and the Cumulative Cohort Design (Ivanova et 
al., 2007). The estimated toxicity rate at current dose is used to decide whether the next cohort is 
treated at current dose or one dose above or below. The rule for dose allocation is as follows: 
i. If ˆ jq ≤ Γ − ∆ , then treat the next cohort at dj+1.  
ii. If ˆ jq ≥ Γ + ∆ , then treat the next cohort at dj-1. 
iii. Otherwise, treat the next cohort at dj. 
The advantage of many non-parametric designs is their simplicity. It is easy to understand 
and to implement with no need of special software. The drawback is that many of these designs 
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do not use all available data in the decision rule and therefore converge slowly to the target dose 
or doses near target. 
 
1.2.2 Parametric designs for dose-finding trials 
In parametric designs, the probability of DLT can be given by a multi-parameter model: 
i
i
dp F α
β
 −
=  
 
 
where α and β is unknown shift and scale parameters (Rosenberger and Haines, 2002). The 
quantile of F is 1( )Fµ α β −= + Γ  where Γ is a specified probability of toxicity and μ can be 
MTD. Two parameters are specified in the probability function and used in designs such as 
escalation with overdose control (EWOC) (Babb et al., 1998). Besides the two-parameter 
models, one parameter model has been also used in designs such as continual reassessment 
method (CRM) (O'Quigley et al., 1990).  
In parametric designs, parameters are estimated using maximum likelihood or Bayesian 
methods. Parametric designs can be realized using maximum likelihood technique in frequentist 
form (O'Quigley and Shen, 1996), however, most of them belong to a class of Bayesian designs 
using Bayesian theorem (O'Quigley et al., 1990). A typical Bayesian decision design has four 
features: (a) a data model, (b) a prior distribution for parameters, (c) loss function, and (d) a set 
of actions (Whitehead, 2006).  Decision of dose allocation is based on the posterior distribution 
of parameter(s) according to Bayesian theorem. To be specific, in one parameter model, the next 
patient is treated at the dose with the toxicity probability close to target p with parameter ϕˆ being 
calculated based on all the outcomes. The next patient will be treated at 
1 ˆ ˆarg min | ( , ) |j k jF d pd ϕ+ = −  (Cheung, 2010).  
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The CRM is a method to find MTD with certain toxicity rate for binary outcome. The one 
parameter working model is ( ) ,  aj jP d a b= where dj is the dose, and j=1,…, K (the dose level), 
and a is a parameter. In a Bayesian form of the CRM, the prior for a is specified, for example, 
f(a)=exp(-a). The posterior mean of parameter a is calculated using all the outcomes. Dose 
assignment is based on mean posterior probability that is closest to the target toxicity rate. The 
CRM can be used to reduce the number of patients to receive lower doses which may far below 
MTD as well and to achieve a more accurate estimation of MTD.  
EWOC is a modified CRM in essence with safety measure to restrict a pre-specified 
proportion of patients to expose to a dose far above MTD. EWOC assigns doses based on the 
posterior probability that is overdosing. The loss function used in EWOC design is  
 ( ) ( )( ) ( )
if    (undose)
,
1 if   (over dose)a
x x
l x
x x
α γ γ
γ
α γ γ
   −      ≤=  − −    >
 
 where γ is the parameter and γ ∈[Xmin, Xmax]. 
Neuenschwander et al. (2008) proposed a Bayesian method which can be used to solve an 
overdose issue too, and defined a rule to assign dose based on maximum posterior probability 
within an interval. The loss function in the approach is 
( )
1
2
3
4
1 if  ( ) (0,0.2]        (under-dosing)           
0 if  ( ) (0.2,0.35]   (Targeted toxicity)        
,
1  if  ( ) (0.35,0.6]    (Excessive toxicity)       
2  if  
l d
l d
L d
l d
l
θ
θ
θ
π
π
θ
π
=     ∈         
=   ∈   
=
=     ∈
=    ( ) (0.6,1]       (Unacceptable toxicity)   dθπ





 ∈
 
Ji et al. ( 2007, 2010) described a rule to assign doses based on the maximum posterior 
probability within an interval. A set of loss functions (Ji et al., 2010) were defined as following, 
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1
1 2
2
,     if         
( , ) ,     if  
 0,      if         
ε
ε ε
ε
− < −
= − ≤ −
>
<
 −
D i T
i D i T
i T
N p p
L D p K p p
p p
 
 
1
1
2
2
,     if         
( , ) 0,       if  
 ,      if         
ε
ε ε
ε
− < −
= − ≤ − <
 − >
S i T
i i T
S i T
N p p
L S p p p
M p p
 
 
1
1
2
2
0,        if         
( , ) ,      if  
 ,      if          
ε
ε ε
ε
− < −
= − ≤ − <
 − >
i T
i E i T
E i T
p p
L E p K p p
M p p
 
where ( , )iL D p  is the loss function for de-escalating,  ( , )iL S p  is for staying, and ( , )iL E p is for 
escalating. 
The advantage of parametric designs over non-parametric designs is that all the available 
information is used to determine the dose for the next patient. On the other hand, parameter 
designs usually are harder to understand and more difficult to use compared to non-parametric 
designs.  
  
1.2.3 Dose-finding for time to event outcome or delayed onset toxicity in Phase I study 
In designs described previously, the outcomes of all previous patients should be known 
before the next patient can be assigned. In many Phase I oncology trials, the follow-up for 
toxicity is rather long. For example, in Lineberger Comprehensive Center trial of a nucleoside 
analog to treat acute myeloid leukemia, patients were observed for DLT for 35 days after the 
start of treatment. The follow-up for toxicity in a Phase I trial of perillyl alcohol at the University 
of Wisconsin Medical School was 4 weeks (Cheung and Chappell, 2000). Yuan (2009) describe 
a Phase I trial where patients were followed for toxicity for 3 months. Therefore, dose-finding 
7 
 
designs using continuous enrollment are needed to solve the problem of mandate trial suspension 
in traditional designs.  
 Several designs have been proposed to incorporate long follow-up time for toxicity in a 
Phase I trial. Two approaches have been used in these designs. 
 Cheung and Chappell (2000) assumed that time to toxicity is distributed uniformly in 
(0, )T given that a DLT was observed in the follow-up window of (0, T). They proposed a 
modified CRM by introducing weight into the likelihood. In TITE-CRM, the dose assignment 
will converge to the MTD as in CRM (Cheung and Chappell, 2002). But due to rapid dose 
escalation, this method may end up with more patients in high toxic doses. Modifications for the 
TITE-CRM have been proposed by Braun et al. (2003, 2006) with the latter describing a 
generalization of TITE-CRM for early- and late-onset toxicities  
The other approach is based on a Bayesian survival analysis methodology. This 
approach requires using Gibbs sampler or Markov Chain Monte Carlo (MCMC) algorithm for 
sampling from probability distributions through constructing a Markov chain to find the desired 
equilibrium distribution.  
Kuo and Smith (1992) detailed how the Gibbs Sampler was used in Bayesian 
computation in survival models, and Rosner described the Gibbs Sampler in monitoring failure-
time endpoints (Rosner, 2005). Yuan (2009) proposed a dose-finding method by jointly 
modeling toxicity and efficacy as time-to-event outcomes. In their study, they used the Cox 
proportional hazards model to model both toxicity and efficacy jointly with Weibull baseline 
hazards; and simulated the posterior distribution through Gibbs sampler assuming non-
informative uniform vague priors. Braun et al. (2005) defined hazard function as a function of 
three parameters and total hazard of toxicity which depends on patient's time on study, number 
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of administrations and the times of treatment; assumed that the general beta distribution priors 
for the parameters and that the hazard increases to the maximum and decrease to zero linearly, 
and calculated the posterior through MCMC simulation to determine the maximum tolerated 
schedule rather than MTD.  
 Often times it takes long to observe toxicity compared to accrual. In some trials, when 
pace of disease is so rapid that a patient may succumb to the disease while waiting, it is desirable 
to enroll a patient into the trial and start treating as soon as possible. None of the existing time to 
event dose methods is suitable in this set up. The method of Bekele et al. (2008) solves the 
problem of fast accrual by prescribing when a trial should be halted as toxicity rate at the current 
dose becomes uncertain. As noted in Cheung and Chappell (2010) rapid accrual, especially in the 
beginning of the trial, may lead to assigning patients to doses with high toxicity rate when TITE-
CRM is used. A rule frequently used is to assign at least 3 patients to a dose and wait for all 3 to 
be fully followed before any more patients can be assigned to that or higher doses. Then, if 
continuous enrollment is desirable, while the first 3 patients are being followed at the current 
dose, patients are assigned to a lower dose. In dose-finding designs (Wetherill, 1963, Ivanova et 
al., 2007) , the next assignment is determined based on the knowledge of the current dose. When 
assignments are being made to lower doses as well as the “current” dose, it is no longer clear 
what dose is the current dose. We describe an easy to use and understand dose-finding method 
where the dose-assignment strategy is not tied to a current dose and the next assignment is made 
to the dose that is most likely to be the MTD. 
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1.2.4 Dose-finding for continuous outcome 
Dose limiting toxicity (yes or no) is the primary endpoint in most oncology phase I trials 
of cytotoxic agents. If a cytostatic agent is being investigated, toxicity is usually not a limiting 
factor and a continuous biomarker endpoint is often used as a primary endpoint, for example a 
measure of target inhibition or pharmacokinetic endpoints such as plasma drug concentrations 
that correlate with biological activity (Le Tourneau et al., 2009), or percentage inhibition of an 
enzyme (Plummer et al., 2008).  Continuous endpoint also arises when multiple toxicity events 
in different body systems and multiple toxicity grades are combined into a single score (Bekele 
and Thall, 2004, Ezzalfani et al., 2012, Chen et al., 2010). A number of scores have been 
proposed recently, for example, total toxicity burden (TTB) (Bekele and Thall, 2004), total 
toxicity profile (TTP) (Ezzalfani et al., 2012), equivalent toxicity score (ETS) (Chen et al., 
2010), and average toxicity score (ATS) (Bekele et al., 2010). These scores are generated 
through combining information from various toxicity grades, grades 1 through 5, into a single 
number with the goal of better reflecting toxicity burden on a patient compared to the binary 
outcome of dose limiting toxicity (DLT) that is usually defined as treatment related non-
hematological toxicity of grade 3 or higher or treatment related hematological toxicity of grade 4 
or higher. 
Many methods in phase I clinical trials are developed for dose-finding with binary 
outcome (DLT, yes or no). Designs for continuous outcome have been proposed through 
controlling dose escalation via a binary assessment of efficacy (Mandrekar et al., 2007, 
Mandrekar et al., 2009, Hunsberger et al., 2005). Several methods work with continuous 
endpoint directly (Ivanova and Kim, 2009, Eichhorn and Zacks, 1973). Dose-finding designs for 
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toxicity score include t-statistics design (Ivanova and Kim, 2009), extended isotonic design 
(Chen et al., 2010), Quasi-CRM (Yuan et al., 2007) , Quasi-Likelihood-CRM (Ezzalfani et al., 
2012) and other designs ( Lee et al., 2010). 
All the methods mentioned earlier require outcome of a patient being observed quickly. 
In many trials, time to observe the outcome is relatively long compared to the accrual rate. In 
some of such trials, for example in trials where urgent treatment is needed, it is desirable to 
assign a dose to a patient as soon as the patient enrolls in the trial. The proposed design allows 
making the best possible assignment for each incoming patient using all information available. 
 
1.3 Other related methods or rules 
In this section we review several methods or rules we have seen in phase I clinical trial 
protocols.  
 
1.3.1 Start-up rule 
It is important to avoid escalation that is too rapid or too slow (Cheung, 2005).  With that 
goal in mind, the group size s in the start-up should be chosen according to the target toxicity 
level Γ.  Ivanova et al. (Ivanova et al., 2003) suggested choosing group size according to the 
following formula ( ) log 0.5 / log(1 Γ)s  = −  .  For example, if Γ = 0.5, the start-up with s = 1 is 
used; if Γ = 0.3, the start-up with s = 2 is used; if Γ = 0.2, the start-up with s = 3 is used. 
 
1.3.2 Isotonic regression                   
In clinical trials, the efficacy or toxicity of a drug is usually assumed to be a non-
decreasing function of dose.  
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Several algorithms have been developed to compute maximum likelihood estimates under 
monotonic restriction. The most widely used one is pool adjacent violator algorithm (PAVA) 
(Barlow et al., 1972) to obtain isotonic estimates. The maximum likelihood estimates for 
1ˆ ˆ ˆ( ,..., ) 'Kµ µ µ= , can be obtained from unrestricted maximum likelihood estimates, 1( ,..., ) 'Ky y  
for 1, 2,...,j K= using max-min formula 
 ˆ min max
j j
t
h h
h s
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h
h s
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n
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∈ ∈
=
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 
 =
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 
 
∑
∑
 
where {1,..., }jL j=  and { ,..., }jU j K=  
PAVA yields restricted MLEs for normal and binomial outcomes when unrestricted 
MLEs are not correlated. Other methods includes simple averaging techniques (Mukarjee, 1988), 
quadratic optimization (Best and Chakravarti, 1990).  
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CHAPTER 2 
LITERATURE REVIEW 2: THE USE OF SELECTIVE PHENOTYPING TO 
INCREASE THE POWER IN GENETICS ASSOCIATION STUDIES 
 
2.1 Introduction 
Blood-based biomarkers and other quantitative measures can provide valuable insights 
into disease etiology and are often used as intermediate outcomes for identifying risk factors 
associated with disease. Genome-wide association studies (GWAS) between quantitative traits 
and single-nucleotide polymorphisms (SNPs) are routinely performed on large samples from 
population-based cohorts. Replication studies are an important step in controlling the type I error 
rate of reported GWAS findings.   Many potential replication cohorts have existing genome-wide 
SNP data but have not yet measured the quantitative trait of interest.  Measuring these traits can 
be expensive and time consuming, which can deter studies from pursuing replication. Given the 
expense and time of measuring these quantitative traits on large samples, it would be desirable to 
identify a subset of subjects that could be phenotyped to optimize statistical power under fixed 
sample size constraints. The goal of this study is to find an approach of utilizing existing 
genotype data to identify an optimal subset of samples to be phenotyped and included in a 
genetic replication study.   
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2.2 Genetic association studies 
Association studies have been widely used for most common diseases such as cancer, 
cardiovascular disease, and diabetes as an alternative strategy to pedigree-based linkage analysis 
studies which have been successfully applied to monogenic Mendelian diseases (Jimenez-
Sanchez et al., 2001, Hirschhorn and Daly, 2005). For more complex diseases, the risk alleles are 
usually more probabilistic, or less penetrant, in increasing the chance of disease and many of the 
causal variants have relatively high frequency in the population. Linkage analysis is not well 
powered for searching for these common variants. Association studies represent a good strategy 
to uncover these variants (Hirschhorn and Daly, 2005, Risch and Merikangas, 1996, Rich, 2000, 
Cardon and Bell, 2001, Tabor et al., 2002, Carlson et al., 2004). While association analyses can 
be based on genotype transmission (from parent to offspring) in pedigrees, an approach designed 
to control for confounded association results due to population stratification (Hirschhorn and 
Daly, 2005, Schork et al., 2001), most genetic association studies are based on unrelated 
individuals. Genetic association studies are widely applied to both quantitative and qualitative 
(case/control) traits. According to scales of variants or single nucleate polymorphisms (SNPs), 
Balding (2006) described four types of association studies: candidate polymorphism (1 SNP), 
candidate gene (5-50 SNPs in a gene), fine-mapping (multiple SNPs in perhaps 5-50 genes), and 
genome-wide (> 300,000 well-chosen SNPs throughout the genome). The recent development of 
next generation sequencing technologies has now lead to a new class of  “gene-burden” rare-
variant association tests, which aggregate information from a defined set (usually some 
collection of variants in the same gene) of multiple variants into a single predictor (Li and Leal, 
2008).  
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2.3 Genome-wide association studies (GWAS) 
Genome-wide association studies (GWAS) that analyze the DNA variation throughout 
genome have become a powerful tool for investigating the role of common human genetic 
variation in common diseases (Bush and Moore, 2012). The goal of GWAS is to identify the 
variants which may be either directly causal or in linkage disequilibrium with the causal 
variant(s) (Hirschhorn and Daly, 2005). In GWAS, the association tests can be performed on a 
single locus with a single SNP, by far the most common application, or on multiple loci 
simultaneously with a combination of multiple SNPs (Bush et al., 2009). In these tests, logistic 
regression models or generalized linear regression models can be fitted for case and control 
studies or for quantitative trait designs, respectively, adjusted for covariates such as age, gender 
and principal components to control for population stratification. If family data or repeated 
measures are included then generalized estimating equations or linear mixed models are typically 
employed. Since usually over half a million SNPs are tested, a Bonferroni correction approach or 
a false discovery rate (FDR) procedure is used to control the rate of false positive results 
(Hochberg and Beniamini, 1990, van den Oord, 2008). Other procedures, such as permutation 
tests, are also occasionally used. It is now standard for top journals to require confirmation of 
new findings from a GWAS using a replication study from an additional independent sample 
(Chanock et al., 2007), which should repeat the design setting as close as possible and should be 
well-powered (Zollner and Pritchard, 2007). 
 
2.4. Cost constraints of genotyping 
Large scale genetic association studies such as GWAS can be prohibitively expensive due 
to the substantial sample sizes required to detect modest genetic effects. Historically, these costs 
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have largely been dominated by the high cost of genotyping. The cost for genotyping a single 
SNP was 0.50 $, later dropped to 0.01$ (Wang et al., 2006). The average cost of genotyping one 
sample was initially thousands of dollars per subject, but today the cost can be as low as a couple 
hundred dollars or less, depending on the genetic marker panel used. Today, GWAS data are 
routinely available on tens of thousands of subjects from deeply phenotyped cohorts. Though the 
expense of phenotyping samples can also be high, since GWAS are routinely performed in large 
“deeply-phenotyped” community based cohorts with existing phenotype data collected from 
earlier epidemiological studies, the major cost constraint, to date, has been the expense of 
genotyping (hundreds dollar per subjects) even though the price is dropping over time.  
 
2.5 Statistical power 
Statistical power is an important consideration for any experiment. Typically these 
calculations are made before initiating the experiment, usually to determine an appropriate 
sample size to achieve a desired probabilistic threshold for success in rejecting the null 
hypothesis in favor of the alternative when the null hypothesis is false. On occasion, post-hoc 
power is calculated after completion of the experiment if the experiment failed to reject the null 
hypothesis. The latter scenario is useful in helping the investigator to assess upper bounds on the 
possible deviation between the true and null values for a parameter of interest.  Statistical power 
is determined by three factors: effect size, sampling error and the statistical significance 
threshold used to reject the null in favor of the alternative (Lipsey and Hurley, 1990).  Effect size 
is the average difference in values between observations from different groups. Power increases 
with increasing effect size. Effect size is typically unknown and specified by the user. The choice 
is sometimes informed by results from previous experiments or by bounds based on meaningful 
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clinical differences. The second factor is sampling error. The larger the sample variability of the 
test statistic the harder it is to reject the null hypothesis. Power can be improved by decreasing 
sampling variability of the test statistic. Increasing sample size is the primary method for 
reducing the sampling variation, but who is sampled can also play an important role in reducing 
the variation. Finally, the statistical significance threshold, i.e. the critical value for the rejection 
region, is an important decision in both controlling power and the type I error. Typically, greater 
concern is applied to controlling the type I error of the experiment. The more stringent the 
applied significance threshold the greater the reduction in power will be. 
 
2.6 Extremes of phenotype for selective genotyping 
One mechanism that has been used to improve power when the extent of genotyping is 
constrained by cost is the utilization of an extremes-of-phenotype design (Darvasi and Soller, 
1992). For a fixed sample size, it is often more powerful to genotype subjects at the opposite 
extreme ends of the phenotype distribution rather than choosing a random sample. Figure 2.1 
demonstrates how we can improve power using extreme phenotype. Assuming that the 
phenotype in a study with two groups A and B, each normally distributed but with different 
means, shown in the upper part of Figure 2.1, we can fit a regression line using all the phenotype 
data from a random sample shown in the left hand of the lower part of Figure 2.1 and fit a 
regression line using a subset of subjects with extreme phenotypes from the same sample shown 
in the right hand of the lower part of Figure 2.1. The slope of the regression line using an 
extreme phenotype sample is often steeper than when using the entire sample. Therefore, we 
create a biased sample that tends to inflate effect size estimates under the alternative model (no 
17 
 
difference under null model) and hence typically increases statistical power over similar sized 
random samples.   
 
2.7 Big data era 
Genome-wide genotype data have been generated on hundreds of thousands of subjects. 
GWAS studies are systematically being performed on existing well-phenotyped biomarkers in 
large cohort studies (McManus, 2009).  10’000s samples from GWAS have been deposited in 
dbGAP --- a database (www.ncbi.nlm.nih.gov/gap) of genotypes and phenotypes--- developed to 
store and distribute genotype and phenotype for association studies and methodology 
development from interested outside researchers (Mailman et al, 2007). Because many large 
cohorts have already been genotyped through GWAS, cost constraints due to genotyping will be 
less of a concern in the near future.  
 
2.8 New biomarkers 
Novel biomarkers are being developed for cardiovascular disease and other disease 
endpoints (Vasan, 2006). The best biomarkers are ones that predict disease such as lipids, 
inflammatory markers (e.g. CRP and IL6), glucose/insulin levels, etc. The rationale for using 
biomarkers in association studies is: 1) Biomarkers may be more proximal to genetic factors that 
play an important role in disease endpoints. 2) Disease endpoints can have very heterogeneous 
etiology and it can be difficult to obtain sufficient numbers of cases to have good power. 
Biomarkers can substitute for clinical endpoints and be used in prognosis of a disease or in 
predicting the state of a disease or clinical benefit (Bhatt et al., 2010). 3) Discovery of genes or 
DNA sequence variation for biomarkers can become good targets for drug development or be 
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used in in personal medicine to provide health care tailed to the individual patient (Kumar and 
Sarin, 2009). 
 
2.9 Cost constraints of phenotyping 
Though many biomarkers are pre-existing in large cohort studies or community based 
studies, not all studies are phenotyped equally. Moreover, it is often difficult to obtain sufficient 
funding to cover the cost of measuring new biomarkers. If there exist  a priori set of genetic 
markers of interest that have already been genotyped, we can select a subset of subjects to 
phenotype that maximizes power. Such a scenario would frequently occur for replication studies, 
where the phenotype of interest has yet to be measured in the replication sample. Another 
possible scenario would be a multistage genetic association study for a new, unmeasured, 
biomarker where a subset of random subjects are phenotyped in stage 1 and a targeted set of 
subjects, based on their genotype data, are phenotyped in stage 2 for variants showing the 
strongest evidence of association in stage 1. 
 
2.10 Extremes of Genotype for selective phenotyping 
One mechanism to increase power when phenotyping is constrained by cost is to use an 
extreme of genotype sampling strategy. The optimal strategy depends on the underlying genetic 
mechanism, but for an additive model this would likely mean preferentially excluding 
heterozygotes in favor of the less common homozygotes. Figure 2.2 illustrates the rationale how 
power can be improved using genotype extremes for a marker that is associated with the 
phenotype of interest. When we fit linear regression models, we often construct Wald or t test 
statistics to test our hypotheses, which include the beta estimate in the numerator and the 
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standard error of the beta estimate in the denominator.  For a fixed sample size, selecting 
extremes of genotype should have little effect, on average, on the numerator (beyond stochastic 
variation) but would typically decrease the variation of the beta estimate (smaller denominator).  
Hence, using genotype extremes will increase our power to reject the null hypothesis in favor of 
the alternative, when true (Sen et al., 2009). For one marker contributing to a phenotype, it is 
easy to optimize the statistical power by simply choosing an equal number of the two 
homozygotes. However, for multiple markers contributing to a phenotype, it is a considerably 
more difficult problem, as there are many tradeoffs when selecting subjects. For example, a 
subject might have the more desirable less common homozygous genotype for one marker but 
have the less desirable heterozygous genotype at several of the other markers of interest. 
Selective phenotyping is about how to select subjects that optimizes power over a distribution of 
markers that are each putatively associated with a phenotype of interest.  
 
2.11 Previous approaches in selective phenotyping 
Existing methods have mainly been described for quantitative trait mapping (QTL), 
mostly in mouse crosses, where the goal is to optimize ability to position a putative causal locus 
in a region of established linkage. One such method is to maximize the recombination events in 
selected subjects. A subject with maximum recombinant across all the markers is selected first, 
and so on until the number of subjects is equal to the sample size (Jannink, 2005, Xu et al., 
2005). The other method is SPARE (Selective Phenotyping Approach by Reduction Entropy) by 
Gagneur et al (2011), a Bayesian mapping approach that is designed to simultaneously optimize 
detection and localization of a QTL using pedigree data. In this method, a genotype-phenotype 
relation model is specified, and the cost function is defined as expected Shannon entropy 
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measuring the uncertainty about a single putative causative QTL. Selection strategy includes 
alternates of a selection step and a phenotyping step until the desired number of subjects is 
selected.  
More relevant approaches to our question of interest, finding associated variants in large-
scale genetic association studies of unrelated subjects, focus on balancing the distribution of 
alleles among subjects across the selected set of variants. In this category, scores like measure of 
similarity are used to find the subset of subjects with genotypes as dissimilar as possible (Sen et 
al., 2009, Jin et al., 2004). The simplest strategy is to, iteratively, select subjects to phenotype 
who have the largest number of homozygous genotypes across all variants (starting with the 
person with the most homozygous genotypes), and repeat until the predefined sample size is 
reached (Sen et al., 2009). This approach is not ideal because it treats all markers equivalently, 
regardless of the underlying alternative models for each, and doesn’t factor in the uneven allele 
frequencies across the markers.  For example, an experimenter might want to maximize power, 
simultaneously, for three markers. Assume two of the markers have common allele frequencies 
and would have excellent power even if a random sample were selected. Assume the third 
marker has considerably lower minor allele frequency and hence it would be critical to carefully 
select the genotypic extremes. Assigning equal weight to all markers when selecting subjects to 
phenotypes would be detrimental to the overall power of the experiment as some subjects with 
the less common homozygous genotype at the third marker would be passed over in favor of the 
subjects homozygous at both of the common markers.  This is a simple example describing the 
largest limitation of existing methods. Namely, existing methods do not directly address the 
power functions of the individual variants when performing sample selection.  The ideal method 
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should be able to directly assess the impact of sample selection on power for all markers 
simultaneously. 
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Figure 2.1 Mechanism to increase power using extreme phenotype. Select a subset of samples 
with extreme phenotype measures from the entire sample. Note, removing subjects from the 
middle of the phenotype distribution results in steeper regression lines than observed for the 
complete sample. 
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 Figure 2.2 Mechanism to increase power using extreme phenotype to use genotype extremes 
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CHAPTER 3 
THE RAPID ENROLLMENT DESIGN FOR PHASE I CLINICIAL TRIALS 
    
3.1 Introduction 
Dose-finding trials in oncology are conducted to learn about the dose-toxicity 
relationship of a drug and to estimate the maximum tolerated dose (MTD). There is a long 
history of oncology dose-finding methods for estimating a dose with a certain mean response 
when outcome is binary (Wetherill, 1963; O'Quigley et al., 1990; Babb et al., 1998). Often it 
takes a long time to observe toxicity compared to accrual rate and a number of methods have 
been developed for dose-finding with delayed outcome (Cheung and Chappell, 2000); (Ivanova 
et al., 2005; Bekele et al., 2008). In some trials, when pace of disease is so rapid that a patient 
may succumb to the disease while waiting, it is desirable to enroll a patient into the trial and start 
treating as soon as possible. None of the existing dose-finding methods developed for delayed 
toxicity is suitable for a trial with rapid enrollment where a patient should be assigned to a dose 
as soon as they are enrolled. The method of Bekele et al. (2008) solves the problem of fast 
accrual by prescribing when a trial should be halted as toxicity rate at the current dose becomes 
uncertain. In TITE-CRM (Cheung and Chappell, 2000) the accrual is not halted and a new 
patient is assigned to the dose closest to the MTD given current data including partial data from 
patients still in follow-up. As noted in Cheung and Chappell (2000) rapid accrual, especially in 
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the beginning of the trial, may lead to assigning patients to doses with high toxicity rate when 
TITE-CRM is used.  
In many dose-finding designs (Wetherill, 1963; Yuan and Chappell, 2004; Ivanova et al., 
2007; Ivanova and Kim, 2009; Ji et al., 2010) the next assignment is determined based on the 
data at the current dose. We propose assigning patients at lower doses while toxicity profile at 
higher doses is uncertain. When assignments are being made to lower doses as well as the higher 
dose, it is no longer clear what dose is the current dose and therefore none of the above cited 
rules can be used for assignment. In this paper we describe an intuitive dose-finding method 
where the dose-assignment strategy is not tied to a current dose and the next assignment is made 
to the dose that is most likely to be the MTD. We refer to the new method as the Rapid 
Enrollment Design (RED). We describe the dose-assignment design in Section 3.2. In Section 
3.3 we propose how to mitigate the uncertainty from patients still in follow-up when a new 
assignment is made. We give an example in Section 3.4. We compare designs in Section 3.5 and 
discuss the findings in Section 3.6.  
 
3.2 Dose-finding method  
Let 1{ ,..., }KD d d=  denote the set of ordered dose levels selected for a trial. Let T be the 
length of follow-up for toxicity. A subject’s response at kd  has Bernoulli distribution with 
parameter qk, where (q1,…,qK) is the vector of true toxicity rates at the K doses. We assume that 
q1,…,qK are non-decreasing, 1 ... Kq q≤ ≤ . Observations from different subjects are independent. 
Only one observation per subject is taken. The goal is to find dose md D∈  such that mq = Γ . If 
there is no such dose, the goal is to find the dose md  with mean response closest to Γ .  We refer 
to Γ  as the target DLT rate and md  as the target dose. 
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 First we consider the case where T is short compared to accrual rate and therefore toxicity 
responses from all patients are known when a new patient is enrolled. In the proposed design, 
each new patient is assigned to the dose with the highest probability of being the target dose 
given data available so far. Let 1( ,..., )Kn n=n  be the number of subjects assigned to each dose 
and 1( ,..., )Km m=m  be the number of DLTs observed at each dose. Then the DLT rates at each 
dose can be estimated by simple proportions ˆ /j j jq m n= , j = 1, …, K. Since 1ˆ ˆ,..., Kq q  might not 
be monotone we will compute isotonic estimates * *1ˆ ˆ( ,..., )Kq q  of DLT rates using the pool adjacent 
violator algorithm (PAVA) (Barlow et al., 1972). PAVA is described as follows. First we set 
*ˆ ˆj jq q= , j =1, …, K. If 1ˆ ˆ... Kq q≤ ≤ , then 
* *
1ˆ ˆ... Kq q≤ ≤  and nothing else is needed. Otherwise, find 
the smallest k such that 1 1/ /k k k km n m n+ +>  and replace these two estimates with 
* *
1 1 1ˆ ˆ ( ) / ( )k k k k k kq q m m n n+ − −= = + + . We also denote the estimate based on pooling data from 
doses kd  and 1kd +  by , 1ˆk kq +  with “dose” , 1k kd +  and weight , 1 1k k k kn n n+ += + . Look again for a 
dose for where the working isotonic estimate is greater than the working estimate at the next 
higher “dose”, and repeat the averaging and concatenation process until isotonicity is actually 
obtained, that is, until * *1ˆ ˆKq q≤ ≤ .  We note that the isotonic estimates are equivalent to the 
maximum likelihood estimates assuming 1 Kq q≤ ≤ . In the dose-assignment design described 
in the next paragraph when estimates * *ˆ ˆ( ,..., )k k mq q + , 
* *ˆ ˆ...k k mq q += = , are computed based on pooled 
data * *ˆ ˆ...k k jq q += = =  ( ... ) / ( ... )k k j k k jm m n n+ ++ + + + , we use the highest dose on the estimated 
plateau, dk+j , to represent the pooled doses if *ˆkq ≤ Γ  and the lowest dose on the estimated 
plateau, dk, if *ˆkq > Γ . To facilitate the Bayesian decision rule described below we assign the 
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average number of DLTs ( ... ) / ( 1)k k jm m j++ + +  and the average sample size 
( ... ) / ( 1)k k jn n j++ + +  of the pooled doses to that dose.   
 To compute the probability of each dose to be the MTD we use Bayesian computations 
and assume Beta(α,β) prior on jq , j = 1, 2,..., K, the posterior distribution of jq  conditional on 
outcome data is  
| , ~ ( , )j j j jq Beta m n mα β+ + −m n , j = 1, 2, ... , K.                        
The prior Beta(α,β) reflects the belief that there exists data from α β+  patients, α  patients with 
DLTs and β  patients without a DLT. We use 0.3α =  and 0.01β = . This prior slows the initial 
escalation because it reflects the prior DLT rate of / ( ) 0.3 / 0.31 0.97α α β+ = = , however it gets 
overruled by data very soon since the effective sample size in the prior is only 0.31α β+ =  of a 
patient.  
Let 1{ ,..., }kd d  be the set of doses with at least one patient assigned. The design is based 
on the following rules 
1) Initial escalation: do not escalate a dose unless at least s patients are assigned to current 
highest dose, k. The number s depends on the target rate Γ, s = 3 is often used if Γ = 0.25. 
2) If *ˆkq < Γ , the next patient is assigned to 1kd +  (or dK  if k = K). 
3) If *ˆkq ≥ Γ , if there is a dose dj such that 
*ˆ jq = Γ , the next patient is assigned to dj. 
Otherwise, let j, 1j k≤ − , be such that *ˆ jq < Γ  and 
*
1ˆ jq + > Γ . Let 
{ }Prj jqπ ε ε= Γ − < < Γ −  and { }1 1Prj jqπ ε ε+ += Γ − < < Γ − . The next patient is 
assigned to the dose corresponding to the higher, jπ  or 1jπ + .  
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4) Do not assign patients to a dose where { }Pr 0.95jq > Γ > , j = 1, 2,..., k. If 
{ }1Pr 0.95q > Γ > , the trial is stopped because the lowest dose is too toxic.  
5) At the end of the trial the dose that would have been recommended for the next patient 
is selected as the estimated MTD. No dose is selected if the lowest dose is deemed too 
toxic by the stopping rule.   
In the rules above, ε , min( ,1 )ε ≤ Γ − Γ , is a design parameter. We recommend 0.05.ε =  
Robustness of this choice is discussed in Section 3.5.  
Decision rules for two candidate doses, one with estimated DLT rate lower than Γ and 
one with rate higher than Γ, are shown in Table 3.1 (for 0.2Γ = ), Table 3.2 (for 0.25Γ = ) and 
Table 3.3 (for 0.3Γ = ). The first column of each of these tables contains data yielding DLT 
proportion less than Γ, and the second column DLT proportion higher than Γ. The decision rule 
for each pair of the first and second column data is in column 3. For example, if 0.2Γ = , 3 
patients were enrolled at dose 1 with no DLTs, and 6 patients were enrolled at dose 2 with 2 
DLTs. The decision rule for these data is to assign the higher dose (line 9, Table 3.1). This is 
because the data at the two doses are (0/3, 2/6) yielding 1 0.090π =  and 2 0.181π = .  
 To implement the RED we developed web-based software available at 
http://www.unc.edu/wang484/red/red.php. The input is the number of DLTs at each dose, 
1( ,..., )km m=m , and the number of subjects at each dose 1( ,..., )Kn n=n . The program identifies 
two candidate doses j and j + 1 based on isotonic estimates, and computes jπ , 1jπ + . It also 
computes the probabilities that the DLT rates at the two doses are higher than Γ needed for the 
safety rule.  
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3.3 Mitigating uncertainty from patients still in follow-up 
In many Phase I oncology trials follow-up time is long compared to accrual rate. Often 3 
patients are assigned to a previously untried dose. These 3 patients need to complete follow-up at 
the dose before more patients can be assigned to that or higher dose level. This however, does 
not fully resolve uncertainty about safety of future assignments. For example, if one out of the 
three patients had a DLT at that dose, can we assign, say, 6 more patients to that dose at once or 
is it too risky? We propose a simple way to mitigate this risk. A patient with a DLT who has 
been in the follow-up for time u and therefore has completed a fraction u/T of the total follow-up 
with 1 /u T−  of the follow-up still remaining is counted as a patient with 1 /u T−  of a DLT. The 
total DLT count at a dose is the number of actual DLTs, m, plus the sum of 1 /iu T− , where the 
sum is over all the patients assigned at that dose that are still in follow-up. The denominator is 
the total number of patients at that dose irrespective of their follow-up time. These data are used 
to determine the next assignment according to the rules in Section 3.2.  
For example, 3 patients have completed follow up at dose 1 with one DLT and several 
patients are available to enroll. If Γ = 0.20, with 1 DTL out of 3, { }1Pr q > Γ  = 0.75, therefore 
since this probability is less than 0.95 at least one more patient can be enrolled. If one patient is 
enrolled, to mitigate potential DLT outcome from this patient, the data are augmented with 1 
DLT at d1 yielding 2/4 DLT at d1 and { }1Pr q > Γ  = 0.93. Since this probability is less than 0.95 
we can enroll one more patient. After augmenting 1/3 with 2/2, for two newly enrolled patients 
with u = 0 follow-up each, the DTL data at d1 are 3/5 yielding { }1Pr q > Γ  = 0.98, therefore we 
cannot assign more patients to d1 at this point. After the two newly enrolled patients have been 
followed for, say, half the total follow-up time without a DLT, the data at  d1 are 1/3 + 0.5/1 + 
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0.5/1 = 2/5 yielding { }1Pr q > Γ  = 0.87 and more patients can be enrolled. Patients are assigned 
to d1 until the estimated DLT rate at d1 becomes lower than Γ = 0.20, at which point patients are 
assigned to d2. 
 In another example, there are 3 patients enrolled at d1 with no DLTs, and 3 patients 
enrolled at d2 with 1 DLT observed in these 3 patients. The data at the two doses are (0/3, 1/3), 
corresponding to 1 0.09π =  and 2 0.15π = , therefore the next patient, patient seven, is assigned to 
d2. If patient eight is available at the time when patient seven is assigned, the augmented data are 
(0/3, 2/4), corresponding to 1 0.09π =  and 2 0.08π = , therefore patient eight should be assigned 
to dose 1. If, instead, patient eight arrives when patient seven has completed half of his follow-up 
without a DLT, the augmented data are (0/3, 1.5/4) yielding 1 0.09π =  and 2 0.14π = , therefore 
patient 8 is assigned to d2. 
 
3.4 Example 
Dose-finding trials in acute leukemia typically require long follow-up for toxicity. This is 
because it is difficult to distinguish undue hematologic drug toxicity from the bone marrow 
effects of the disease itself. Often this requires follow-up for toxicity from an individual cycle of 
therapy that lasts 4-6 weeks rather than what is typical in solid tumors (3-4 weeks).  In addition it 
is desirable to offer continuous enrollment in acute leukemia trials, since the pace of these 
leukemias is so rapid that the patient may succumb to the disease while waiting.  The proposed 
strategy was implemented in a dose-finding study of a new derivative of thalidomide for older 
adults with acute myeloid leukemia. Since the trial is ongoing, we used data from a recently 
completed Phase I trial (Foster et al., 2012) to illustrate the method. The trial investigated 
clofarabine in combination with gemtuzumab ozogamicin in relapsed or refractory acute myeloid 
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leukemia patients. The DLT was defined as grade 3 or greater treatment-related toxicity lasting 
greater than 2 weeks or delay in hematologic recovery beyond 35 days from initiation of 
induction and not related to persistent or recurrent leukemia. Therefore the maximum 
observation period for toxicity was 5 weeks from the start of therapy, and the goal of the trial 
was to find a dose with the DLT rate of 0.26. The trial used the time-to-event CCD method from 
Ivanova et al. (2007) with an ad-hoc modification that allowed rapid enrollment with immediate 
assignment. We illustrate how the proposed dose-assignment algorithm would have worked if 
used in the gemtuzumab trial. We use patient enrollment times, their DLT outcomes and the time 
when a DLT has occurred. There were three patients who progressed or died between days 32 
and 35 without a DLT, and therefore these patients were permanently censored for DLT before T 
= 35. In this illustration these patients are counted as patients with full follow-up of 35 days and 
no DLT. Dose assignments for the first 18 patients are presented in Table 3.4. When patient 19 
was enrolled, all 13 patients assigned to dose 1 have completed their follow-up and 5 DLTs were 
observed. The posterior probability that the DLT rate at d1 exceeds 0.26 is 0.85, and therefore 
according to our method the next assignment should be to d1. In the actual acute myeloid 
leukemia trial, after seeing these data, the investigators decided to be conservative and to enroll 
patients 19 and 20 at the lower dose, dose -1.  
 
3.5 Comparisons with other dose-finding methods 
3.5.1 Comparison with mTPI and the t-statistic designs in trials with a short follow-up time  
First we considered the case where DLT outcome is known right away. We compared the 
RED with the modified toxicity probability interval (mTPI) method (Ji et al., 2010), and the t-
statistics design (Ivanova and Kim, 2009).  
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The mTPI is based on computing Bayesian posterior probabilities of the DLT rate being 
in certain intervals. Let dj be the current dose, that is, the dose the last patient was assigned to. 
Calculate three probabilities { }1 1Pr 0 / ( )jE q ε ε= < < Γ − Γ − , 
{ }1 2 2 1Pr / ( )jS qε ε ε ε= Γ − < < Γ + +  and { }2 2Pr 1 / (1 )jD qε ε= Γ + < < − Γ − .  The next patient 
is assigned to dj+1 if E is the largest, to dj if S is the largest, and to dj-1 if D is the largest. If 
{ }Pr 0.95jq > Γ > , patients are assigned to lower doses. If { }1Pr 0.95q > Γ >  the trial is stopped. 
The estimated MTD is the dose with the estimated DLT rate closest to Γ. 
 The t-statistics method is a dose-finding design in which the t-statistic, T, to test the 
hypothesis that the mean at the current dose is equal to the target is computed at each step. The 
next patient is assigned to the current dose if T−∆ < < ∆ , otherwise the dose is reduced or 
increased depending on the sign of T. Here Δ is a design parameter and Δ = 1 is recommended. 
In the t-statistic design to estimate the target dose after the trial for the new design, we first 
obtained the isotonic estimates of DLT rates. The dose with the estimated DLT rate closest to Γ 
is the estimated MTD.  If there were two or more such doses, the highest dose with the estimated 
DLT rate below Γ is chosen. If all the estimated rates at these doses were higher than Γ, the 
lowest of these doses is chosen. 
   We used all 10 scenarios from Ji et al. (2010) to compare designs. Results for mTPI for 
scenarios 1, 5, 7-10 were reproduced from Ji et al. (2010) and results for scenarios 2-4 and 6 
were simulated using the program provided by Yaun Ji. Simulations were performed in R and 
comparison is made based on 4000 simulation runs for each scenario. The target DLT rate was 
0.25Γ = . In all designs patients are assigned in cohorts of 3 and response is observed 
immediately. Note that all three designs can be used with any number of patients per cohort, 
assignment in cohorts of 3 was chosen to match the simulations in Ji et al. (2010). In the RED we 
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set 0.3α = , 0.01β =  and 0.05ε = . Larger value of α  is chosen to slow down escalation when 
there is not much information available at the dose. In mTPI design the prior parameters are 
1α = , 1β =  as in Ji et al. (2010). Since Ji et al. (2010), used α and β different from ours we 
calibrated our safety rule so that the two designs make the same safety decision for the same 
data. The re-calibrated safety rule for our design is that patients are not assigned to a dose if 
{ }Pr 0.96jq > Γ > .  
 Overall all three designs perform very similarly (Table 3.5). In scenario 7 the t-statistics 
design recommends the target dose (dose with the DLT rate of 0.05) in 0.46 of the trials 
compared to 0.82 and 0.83 for the other two designs. This is because a safety rule was 
implemented in RED and mTPI design but not in the t-statistic design. A frequentist safety rule 
for the t-statistic design can be constructed similarly to the Bayesian safety rule described in 
Section 3.3.  
  We investigated the robustness of the new design with respect to parameter ε . In the 
main simulation study (Table 3.5) we used ε  = 0.05. We performed simulations with values of 
ε  in the range (0.01, 0.1) and obtained very similar results (results are available from the 
authors).    
   
3.5.2 Comparison with TITE-CRM when the follow-up for DLT is long  
Cheung and Chappell (2000) proposed a time-to-event modification of the continual 
reassessment method (CRM), called TITE-CRM, for dose-finding trials where follow-up for 
DLT is long. Let xi be the dose level received by subject i, xi ∈ D, and yi = 1 if the ith subject had 
a DLT and 0 otherwise. In the original CRM (O’Quigley et al., 1990), the calculation of posterior 
mean of θ at the time when (n+1)th subject enters the trial is based on the likelihood: 
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1
( ) ( , ) 1 ( , ) ,ii
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n i i
i
L F x F xθ θ θ −
=
= −∏  
where ( , )
ii x
F x bθθ =  and 1( ,..., )Kb b  is a set of positive constants. In clinical trials that require 
long follow-up times, the toxicity rate at dose ix  is defined as the probability of observing 
toxicity at ix  during a time period of length T after initiation of therapy. Data for the ith subject, 
i = 1,…, n, when (n+1)th subject is assigned to a treatment, consists of dose xi, toxicity indicator 
iy  and the time iu  that has elapsed from the  time of the ith subject’s treatment assignment to the 
time of the (n+1)th subject’s treatment assignment.   
 For TITE-CRM, Cheung and Chappell (2000) suggested the weighted likelihood 
{ } { }1
1
( ) ( , ) 1 ( , ) ,i i
n
y y
n i i i i
i
L w F x w F xθ θ θ −
=
= −∏  
where iw  is the weight assigned to the ith observation prior to the entry of the (n+1)th subject. 
For example, setting min( / ,1)i iw u T=  reflects an assumption that the density of time to toxicity 
is flat in (0,T).  
 We compared the performance of the TITE-CRM and the RED via simulations. In the 
RED the uncertainty from patients still in follow-up was mitigated as described in Section 3. 
Note that the approaches of handling patients still in follow up in the TITE-CRM and in the RED 
are very different. In the TITE-CRM, a patient who has been followed for a fraction w of full 
follow-up time T and have not had a DLT yet is contributing roughly as a fractional patient (w of 
a patient) without a DLT. On the other hand, in our approach such a patient is contributing as 1 
patient with (1 – w) DLTs. As a result, if many patients are enrolled at once, the TITE-CRM 
escalates rapidly to higher doses and our method is conservative and escalates slowly.  
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 Table 6 displays comparison of the two designs in a trial with 35-day follow up for DLT. 
Patients are assigned one at a time and enrolled at the rate of one patient per week. For patients 
with DLT, time to DLT was generated as uniform random variable on (0,35). We excluded 
scenario 8 since there is no MTD in this scenario. Due to aggressive escalation the TITE-CRM 
recommends the doses above the true MTD much more frequently than the RED. At the same 
time the recommendation of the correct dose is similar between the two designs. The RED 
recommends the correct MTD more often in scenarios where the MTD is among lower doses and 
the TITE-CRM recommends the correct MTD more often when the MTD is among higher doses. 
This is because the TITE-CRM escalates rapidly and the RED is conservative. Rapid escalation 
of the TITE-CRM to higher doses leads to observing 3 more DLTs on average in each trial 
compared to the RED.  
 The average length of a trial is 51 weeks. For comparison a trial that enrolls patients in 
cohorts of 3 at a time where each cohort is followed for 5 weeks before the next cohort is 
enrolled will have the length of approximately 70 weeks. The results of the latter are the same as 
those presented in Table 5. Comparison of Table 5 and 6 shows that the RED can provide good 
estimation of the MTD in trials with long follow-up for toxicity without exposing patients to 
doses with possibly high DLT rates.  
 
3.6 Discussion 
We proposed a new method to assign patients to doses in a Phase I oncology trial and a 
method to mitigate uncertainty from patients still in follow-up. Ji and Wang (2013) recently 
compared the mTPI and the 3+3 designs (Storer, 1989), to show that mTPI can identify the 
correct MTD better and also assigns fewer patients to the toxic doses above MTD. Our new 
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method performs similar to mTPI but also has flexibility to accommodate rapid enrollment in 
trials with long follow-up. We give tables with decision rules to implement the new design. A 
web-based program is available to identify a dose for the next assignment given trial data.  
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Table 3.1 Dose allocation decision based on the posterior probability at two candidate doses dj 
and dj+1. Target probability is Γ = 0.20. The observed toxicity rate at dj is less than Γ and the 
observed toxicity rate at dj+1 is higher than Γ. Data at each dose is the number of DLTs over the 
number of patients assigned to the dose.  
 
Observed data at jd   Observed data at 1jd +  Decision 
1/6:12,  2/11:12 1/3,  2/5, 3/8, 4/10, 4/11 Lower Dose 
1/6:11,  2/11:12 2/6, 3/9, 4/12 Lower Dose 
2/11:12 2/7,  3/10,1/4, 2/8:9, 
3/11:12 
Lower Dose 
1/6:7 3/10 Lower Dose 
1/6:8 2/7 Lower Dose 
1/6:10 1/4 Lower Dose 
0/1:12 1/3,  2/5,  3/8,  4/10:11 Higher Dose 
0/1:12, 1/12   2/6, 3/9,  4/12 Higher Dose 
0/1:12,  1/6:12 2/8:9,  3/11:12 Higher Dose 
0/1:12,  1/11:12 1/4 Higher Dose 
0/1:12,  1/9:12 2/7 Higher Dose 
0/1:12,  1/8:12 3/10 Higher Dose 
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Table 3.2 Dose allocation decision based on the posterior probability at two candidate doses dj 
and dj+1. Target probability is Γ = 0.25. The observed toxicity rate at dj is less than Γ and the 
observed toxicity rate at dj+1 is higher than Γ. Data at each dose is the number of DLTs over the 
number of patients assigned to the dose. 
Observed data at jd  Observed data at 1jd +  Decision 
1/5:12, 2/9:12 1/2, 2/4, 3/6 Lower Dose 
1/5:9, 2/9:12 1/3, 2/5, 3/7 Lower Dose 
2/9:12 2/6, 2/7, 3/9, 4/11 Lower Dose 
2/9:11 4/12 Lower Dose 
2/9:11 4/12 Lower Dose 
1/5:6, 2/9:12 3/8 Lower Dose 
1/5:8, 2/9:12 4/10 Lower Dose 
1/5:9, 2/9:12 5/12 Lower Dose 
1/5:10, 2/9:12 4/9 Lower Dose 
1/5:11, 2/9:12 5/11 Lower Dose 
0/1:2, 1/5:12, 2/9:12 4/8 Lower Dose 
0/1:3, 1/5:12, 2/9:12 5/10 Lower Dose 
0/1:4, 1/5:12, 2/9:12 6/12 Lower Dose 
0/1:6, 1/5:12, 2/9:12 6/11 Lower Dose 
0/1:12 1/2, 2/4, 3/6 Higher Dose 
0/1:12, 1/10:12 1/3, 2/5, 3/7, 5/12 Higher Dose 
0/1:12, 1/5:12 2/6:7, 3/9, 4/11 Higher Dose 
0/1:12, 1/5:12, 2/9:12 3/10:11 Higher Dose 
0/7:12 6/11 Higher Dose 
0/5:12 6/12 Higher Dose 
0/4:12 5/10 Higher Dose 
0/3:12 4/8 Higher Dose 
0/1:12,1/12 5/11 Higher Dose 
0/1:12,1/11:12 9/4 Higher Dose 
0/1:12, 1/9:12 4/10 Higher Dose 
0/1:12, 1/7:12 3/8 Higher Dose 
0/1:12, 1/5:12, 2/12 4/12 Higher Dose 
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Table 3.3 Dose allocation decision based on the posterior probability at two candidate doses dj 
and dj+1. Target probability is Γ = 0.30. The observed toxicity rate at dj is less than Γ and the 
observed toxicity rate at dj+1 is higher than Γ. Data at each dose is the number of DLTs over the 
number of patients assigned to the dose. 
 
Observed data at jd  Observed data at 1jd +  Decision 
1/4:9, 2/7:12, 3/11:12 1/2, 6/12 Lower Dose 
1/4:6, 2/7:12, 3/11:12 1/3, 5/11 Lower Dose 
1/4:8, 2/7:12, 3/11:12 2/4, 3/6, 4/8, 5/10 Lower Dose 
1/4:5, 2/7:12, 3/11:12 2/5, 4/9 Lower Dose 
2/7:10, 3/11:12 2/6, 5/12 Lower Dose 
3/11:12 3/9, 4/11 Lower Dose 
1/5, 2/7:11, 3/11:12 3/7 Lower Dose 
2/7:9, 3/11:12 3/8, 4/10 Lower Dose 
0/1, 1/4:11, 2/7:12, 3/11:12 6/11 Lower Dose 
0/1:12, 1/10:12 1/2, 6/12 Higher Dose 
0/1:12, 1/7:12 1/3, 5/11 Higher Dose 
0/1:12, 1/9:12 2/4, 3/6, 4/8, 5/10 Higher Dose 
0/1:12, 1/6:12 2/5, 4/9 Higher Dose 
0/1:12, 1/4:12, 2/11:12 2/6, 5/12 Higher Dose 
0/1:12, 1/4:12, 2/7:12 3/9, 4/11 Higher Dose 
0/1:12, 1/4:12, 2/12 3/7 Higher Dose 
0/1:12, 1/4:12, 2/10:12 3/8, 4/10 Higher Dose 
0/1:12, 1/4:12, 2/7:12, 3/11:12 4/12 Higher Dose 
0/2:12, 1/12 6/11 Higher Dose 
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Table 3.4 Dose assignments for the first 18 patients in the gemtuzumab trial. The target DLT 
rate is 0.26. The length of follow-up is 35 days. DLTs were observed on patients 4, 9, 11, 12, 14, 
16 and 17.  
 
Pt Day 
of 
enroll
ment 
Data from 
patients with 
full follow-up 
at the time of 
enrollment  
Additional 
temporary 
DLTs from 
patients still in 
follow-up at the 
time of 
enrollment 
Estimated 
DLT rate  
Posterior 
probability that 
DLT rate is in 
(0.21, 0.31) 
Dose 
Assi
gnm
ent 
  d1  d2 d1 d2 d1 d2 d1 d2  
  1 1  --- --- --- --- --- --- --- --- 1 
2 77  0/1 --- 0/0 --- 0.00 --- 0.078 --- 1 
3 77  0/1 --- 0/0 --- 0.00 --- 0.087 --- 1 
4 172  0/3 --- 0/0 --- 0.00 --- 0.064 --- 2 
5 194  0/3 0/0 0/0 0.37/1 0.00 0.37 0.064 0.082 2 
6 327  0/3 1/2 0/0 0/0 0.00 0.50 0.064 0.087 2 
7 327  0/3 1/2 0/0 1/1 0.00 0.67 0.064 0.041 1 
8 348  0/3 1/2 0.4/1 0.4/1 0.10 0.47 0.127 0.108 1 
9 369  0/4 1/3 0.4/1 0/0 0.08 0.33 0.113 0.148 2 
10 437  0/5 2/4 0/0 0/0 0.00 0.50 0.042 0.098 2 
11 448  0/5 2/4 0/0 0.69/1 0.00 0.54 0.042 0.077 2 
12 508  0/5 3/6 0/0 0/0 0.00 0.50 0.042 0.093 2 
13 516  0/5 3/6 0/0 0.77/1 0.00 0.54 0.042 0.065* 1 
14 565  0/6 4/7 0/0 0/0 0.00 0.57 0.033 0.047* 1 
15 636  1/7 4/7 0/0 0/0 0.14 0.57 0.176 0.047* 1 
16 671  1/8 4/7 0/0 0/0 0.13 0.57 0.159 0.047* 1 
17 676  1/8 4/7 0.86/1 0/0 0.23 0.57 0.250 0.047* 1 
18 801  3/10 4/7 0/0 0/0 0.30 0.57 0.270 0.047* 1 
19 815  3/10 4/7 0.60/1 0/0 0.33 0.57 0.260 0.047* 1 
20 850  3/12 4/7 0/0 0/0 0.25 0.57 0.307 0.047* 1 
 
*The probability that the DLT rate exceeds 0.26 is higher than 0.95 
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Table 3.5 Comparison of the mTPI, the proposed RED method and the t-statistics design. The 
target DLT rate is 0.25 and the total sample size is n = 30. Proportion of times each dose is 
recommended as the target dose and the average number of subjects allocated to each dose.  
Numbers at the target dose are in bold.  
 
 d1 d2 d3 d4 d5 d6 d7 d8 
Scenario 1 0.05 0.25 0.50 0.60 0.70 0.80 0.90 0.95 
Recommendation      mTPI 0.14 0.78 0.08 0.00 0.00 0.00 0.00 0.00  
                               RED  0.14 0.77 0.09 0.00 0.00 0.00 0.00 0.00 
                                 t-statistics  0.14 0.78 0.08 0.00 0.00 0.00 0.00 0.00 
Allocation                mTPI 7.1 18.3 4.4 0.2 0.0 0.0 0.0 0.0 
                               RED 6.8 17.5 5.1 0.6 0.0 0.0 0.0 0.0 
                                  t-statistics 7.5 17.6 4.5 0.3 0.0 0.0 0.0 0.0 
         
Scenario 2 0.01 0.05 0.25 0.50 0.60 0.70 0.80 0.90 
Recommendation      mTPI 0.00 0.14 0.74 0.11 0.01 0.00 0.00 0.00 
                               RED  0.00 0.15 0.75 0.10 0.00 0.00 0.00 0.00 
                                 t-statistics  0.04 0.10 0.78 0.09 0.00 0.00 0.00 0.00 
Allocation                mTPI 3.3 6.6 15.7 4.0 0.4 0.0 0.0 0.0 
                               RED 3.2 6.7 15.0 4.6 0.6 0.0 0.0 0.0 
                                  t-statistics 3.2 7.0 15.3 4.1 0.3 0.0 0.0 0.0 
         
Scenario 3 0.01 0.02 0.05 0.25 0.50 0.60 0.70 0.80 
Recommendation      mTPI 0.00 0.00 0.13 0.75 0.11 0.01 0.00 0.00 
                               RED  0.00 0.00 0.15 0.73 0.11 0.01 0.00 0.00 
                                 t-statistics  0.00 0.00 0.14 0.76 0.10 0.00 0.00 0.00 
Allocation                mTPI 3.2 3.5 6.2 13.1 3.8 0.3 0.0 0.0 
                               RED 3.1 3.4 6.5 12.5 4.0 0.5 0.0 0.0 
                                  t-statistics 3.2 3.5 6.3 13.0 3.6 0.3 0.0 0.0 
         
Scenario 4 0.01 0.02 0.03 0.05 0.25 0.50 0.60 0.70 
Recommendation      mTPI 0.00 0.00 0.00 0.14 0.69 0.15 0.02 0.00 
                               RED  0.00 0.00 0.00 0.15 0.73 0.10 0.01 0.00 
                                 t-statistics  0.00 0.00 0.00 0.16 0.71 0.12 0.01 0.00 
Allocation                mTPI 3.2 3.5 3.5 5.6 10.7 3.2 0.3 0.0 
                               RED 3.1 3.3 3.5 6.2 10.0 3.4 0.4 0.0 
                                  t-statistics 3.2 3.5 3.7 5.8 10.5 3.0 0.2 0.0 
         
Scenario 5 0.01 0.02 0.03 0.04 0.05 0.25 0.50 0.60 
Recommendation      mTPI 0.00 0.00 0.00 0.02 0.16 0.71 0.10 0.01 
                               RED  0.00 0.00 0.00 0.01 0.24 0.61 0.12 0.01 
                                 t-statistics  0.00 0.00 0.00 0.02 0.16 0.69 0.11 0.01 
Allocation                mTPI 3.2 3.5 3.6 4.0 5.2 8.1 2.3 0.1 
                               RED 3.1 3.3 3.5 3.6 5.6 7.7 2.8 0.4 
                                  t-statistics 3.2 3.5 3.7 4.0 5.1 8.1 2.2 0.2 
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Scenario 6 0.01 0.02 0.03 0.04 0.05 0.06 0.25 0.50 
Recommendation      mTPI 0.00 0.00 0.00 0.02 0.04 0.28 0.50 0.15 
                               RED  0.00 0.00 0.00 0.01 0.04 0.25 0.55 0.14 
                                 t-statistics  0.00 0.00 0.00 0.02 0.04 0.29 0.51 0.13 
Allocation                mTPI 3.2 3.4 3.8 3.8 4.0 4.7 5.3 1.8 
                               RED 3.1 3.3 3.5 3.6 3.7 4.8 5.6 2.5 
                                  t-statistics 3.2 3.5 3.7 4.0 4.0 4.6 5.3 1.7 
         
Scenario 7 0.01 0.05 0.50 0.60 0.70 0.80 0.90 0.95 
Recommendation      mTPI 0.00 0.82 0.17 0.00 0.00 0.00 0.00 0.00 
                               RED  0.00 0.81 0.19 0.01 0.00 0.00 0.00 0.00 
                                 t-statistics  0.27 0.46 0.26 0.00 0.00 0.00 0.00 0.00 
Allocation                mTPI 3.2 15.9 10.3 0.6 0.0 0.0 0.0 0.0 
                               RED 3.2 15.9 9.9 1.0 0.1 0.0 0.0 0.0 
                                  t-statistics 3.2 16.0 10.1 0.7 0.0 0.0 0.0 0.0 
         
Scenario 8 0.40 0.50 0.60 0.70 0.80 0.90 0.95 0.99 
Recommendation      mTPI 0.31 0.03 0.00 0.00 0.00 0.00 0.00 0.00 
                               RED  0.34 0.02 0.00 0.00 0.00 0.00 0.00 0.00 
                                 t-statistics  0.32 0.02 0.00 0.00 0.00 0.00 0.00 0.00 
Allocation                mTPI 16.8 2.0 0.2 0.0 0.0 0.0 0.0 0.0 
                               RED 16.3 2.8 0.3 0.0 0.0 0.0 0.0 0.0 
                                  t-statistics 16.9 1.9 0.2 0.0 0.0 0.0 0.0 0.0 
         
Scenario 9 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 
Recommendation      mTPI 0.29 0.45 0.20 0.04 0.00 0.00 0.00 0.00 
                               RED  0.27 0.45 0.21 0.04 0.00 0.00 0.00 0.00 
                                 t-statistics  0.30 0.45 0.20 0.04 0.00 0.00 0.00 0.00 
Allocation                mTPI 12.4 10.9 5.0 1.1 0.1 0.0 0.0 0.0 
                               RED 10.7 11.6 5.6 1.5 0.3 0.0 0.0 0.0 
                                  t-statistics 11.9 11.7 4.9 1.1 0.1 0.0 0.0 0.0 
         
Scenario 10 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 
Recommendation      mTPI 0.02 0.28 0.42 0.23 0.04 0.00 0.00 0.00 
                               RED  0.03 0.29 0.43 0.21 0.04 0.01 0.00 0.00 
                                 t-statistics  0.03 0.30 0.44 0.19 0.03 0.00 0.00 0.00 
Allocation                mTPI 4.9 10.2 9.4 4.5 0.9 0.1 0.0 0.0 
                               RED 4.7 9.6 9.5 4.6 1.3 0.2 0.0 0.0 
                                  t-statistics 5.0 10.4 9.7 3.9 0.8 0.1 0.0 0.0 
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Table 3.6 Proportion of trials each dose was recommended as the MTD by the TITE-CRM and 
the RED. The length of follow-up for DLT is 35 days with enrollment rate of 1 patient per week. 
The target DLT rate is 0.25 and the total sample size is n = 30. Numbers at the target dose are in 
bold.  
 
  
 d1 d2 d3 d4 d5 d6 d7 d8 
Scenario 1 0.05 0.25 0.50 0.60 0.70 0.80 0.90 0.95 
Recommendation   TITE-CRM   0.11 0.72 0.16 0.00 0.00 0.00 0.00 0.00 
                               RED   0.11 0.81 0.08 0.00 0.00 0.00 0.00 0.00 
Allocation              TITE-CRM   6.6 14.5 7.2 1.3 0.4 0.1 0.0 0.0 
                               RED   11.0 15.5 3.2 0.3 0.0 0.0 0.0 0.0 
         
Scenario 2 0.01 0.05 0.25 0.50 0.60 0.70 0.80 0.90 
Recommendation   TITE-CRM   0.00 0.09 0.73 0.17 0.01 0.00 0.00 0.00 
                               RED   0.00 0.13 0.80 0.07 0.00 0.00 0.00 0.00 
Allocation              TITE-CRM   3.1 5.2 13.3 6.7 1.3 0.4 0.0 0.0 
                               RED   3.7 10.3 13.0 2.7 0.2 0.0 0.0 0.0 
         
Scenario 3 0.01 0.02 0.05 0.25 0.50 0.60 0.70 0.80 
Recommendation   TITE-CRM   0.00 0.00 0.12 0.69 0.18 0.01 0.00 0.00 
                               RED   0.00 0.01 0.18 0.73 0.08 0.00 0.00 0.00 
Allocation              TITE-CRM   3.1 3.1 5.2 11.1 6.0 1.3 0.2 0.0 
                               RED   3.4 4.2 9.0 10.7 2.5 0.2 0.0 0.0 
         
Scenario 4 0.01 0.02 0.03 0.05 0.25 0.50 0.60 0.70 
Recommendation   TITE-CRM   0.00 0.00 0.00 0.15 0.64 0.20 0.01 0.00 
                               RED   0.00 0.01 0.05 0.21 0.65 0.09 0.00 0.00 
Allocation              TITE-CRM   3.1 3.1 3.3 5.1 9.5 5.1 0.9 0.0 
                               RED   3.4 3.9 4.5 7.6 8.4 2.0 0.2 0.0 
         
Scenario 5 0.01 0.02 0.03 0.04 0.05 0.25 0.50 0.60 
Recommendation   TITE-CRM   0.00 0.00 0.00 0.01 0.16 0.64 0.18 0.01 
                               RED   0.00 0.00 0.05 0.12 0.19 0.55 0.08 0.00 
Allocation              TITE-CRM   3.0 3.0 3.2 3.6 5.1 8.2 3.5 0.3 
                               RED   3.4 4.0 4.5 4.6 5.7 6.0 1.7 0.2 
         
Scenario 6 0.01 0.02 0.03 0.04 0.05 0.06 0.25 0.50 
Recommendation   TITE-CRM   0.00 0.00 0.00 0.01 0.04 0.23 0.61 0.12 
                               RED   0.00 0.01 0.05 0.12 0.12 0.21 0.42 0.08 
Allocation              TITE-CRM   3.0 3.0 3.2 3.6 4.0 5.2 6.3 1.6 
                               RED   3.4 4.0 4.4 4.5 4.2 4.1 4.1 1.2 
         
Scenario 7 0.01 0.05 0.50 0.60 0.70 0.80 0.90 0.95 
Recommendation   TITE-CRM   0.00 0.52 0.47 0.01 0.00 0.00 0.00 0.00 
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                               RED   0.00 0.56 0.44 0.00 0.00 0.00 0.00 0.00 
Allocation              TITE-CRM   3.4 11.5 12.0 2.5 0.4 0.3 0.0 0.0 
                               RED   3.7 18.5 7.1 0.6 0.0 0.0 0.0 0.0 
         
Scenario 9 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 
Recommendation   TITE-CRM   0.19 0.48 0.29 0.04 0.00 0.00 0.00 0.00 
                               RED   0.36 0.48 0.14 0.02 0.00 0.00 0.00 0.00 
Allocation              TITE-CRM   9.0 10.8 7.3 2.1 0.6 0.1 0.0 0.0 
                               RED   16.1 10.0 3.2 0.6 0.1 0.0 0.0 0.0 
         
Scenario 10 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 
Recommendation   TITE-CRM   0.01 0.17 0.49 0.28 0.05 0.00 0.00 0.00 
                               RED   0.03 0.41 0.43 0.12 0.01 0.00 0.00 0.00 
Allocation              TITE-CRM   3.9 6.8 10.6 6.2 2.0 0.5 0.1 0.0 
                               RED   7.3 12.0 7.7 2.4 0.5 0.1 0.0 0.0 
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CHAPTER 4 
DOSE-FINDING FOR CONTINUOUS OUTCOME IN PHASE I ONCOLOGY TRIALS 
 
4.1 Introduction 
Dose limiting toxicity (yes or no) is the primary endpoint in most oncology Phase I trials 
of cytotoxic agents. If a cytostatic agent is being investigated, toxicity is usually not a limiting 
factor. For example, out of 82 recent Phase I trials with cytostatic drugs reviewed by (Penel et 
al., 2011) dose limiting toxicity (DLT) was reached in 43 (52%) of the trials. Therefore, a 
continuous biomarker endpoint might be a better primary endpoint in a Phase I trial. Examples 
include a measure of target inhibition or pharmacokinetic endpoints such as plasma drug 
concentrations that correlate with biological activity (Le Tourneau et al., 2009), or percentage 
inhibition of an enzyme (Plummer et al., 2008).   
Continuous endpoint also arises when multiple toxicity events in different body systems 
and multiple toxicity grades are combined into a single score (Bekele and Thall, 2004; Ezzalfani 
et al., 2012); Chen et al., 2010). Binary endpoint of DLT used in most of Phase I trials is defined 
as treatment related non-hematological toxicity of grade 3 or higher or treatment related 
hematological toxicity of grade 4 or higher. Wang et al. (2000) showed that the maximum 
tolerated dose (MTD) can be identified more accurately through incorporating the information on 
grade 3 and grade 4 toxicity instead of using DLT. The MTD is then defined as the dose with a 
certain mean toxicity score. Example of toxicity scores proposed recently include total toxicity 
burden (Bekele and Thall, 2004), equivalent toxicity score (Chen et al., 2010), average toxicity 
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score (ATS) (Bekele et al., 2010), and total toxicity profile (Ezzalfani et al., 2012). These scores 
are computed by combining information from various toxicity grades and various types of 
toxicity into a single number with the goal of better reflecting toxicity burden on a patient 
compared to the binary outcome of a DLT. 
 Dose-finding designs for continuous outcome have been proposed through controlling 
dose escalation via a dichotomized outcome (Mandrekar et al., 2007, Mandrekar et al., 2009, 
Hunsberger et al., 2005). Several methods work with the continuous endpoint directly (Ivanova 
and Kim, 2009, Eichhorn and Zacks, 1973). Dose-finding designs for toxicity score include quasi 
continual reassessment method (Yuan et al., 2007), extended isotonic design (Chen et al., 2010), 
the design in (Ezzalfani et al., 2012, Lee et al., 2010) and quasi-likelihood continual 
reassessment method of Ezzalfani et al. (2012). The t-statistics design (Ivanova and Kim, 2009) 
can also be used in trials with toxicity score as primary endpoint. All the methods mentioned 
earlier require outcome of a patient to be observed quickly. In many trials, time to observe the 
outcome is long compared to the accrual rate. In such trials when urgent treatment is needed, it is 
desirable to assign a dose to a patient as soon as the patient enrolls in the trial. The proposed 
design allows making the best possible assignment for each incoming patient using all 
information available. 
In Section 4.2, we describe the proposed method. We give an example in Section 4.3. 
Simulation results are presented in Section 4.4 and discussion in Section 4.5.  
4.2 Notation and methods 
4.2.1 Probability model  
Let 1{ ,..., }KD d d=  be the set of ordered dose levels selected for a trial. Let Yj be the 
outcome at dose jd , j = 1,…, K, 
2~ ( , )j j jY N µ σ . We assume that both mean μj and variance 
2
jσ  
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are unknown. The goal is to find a dose md D∈  with the mean response closest to the target 
response η. We assume that mean responses are non-decreasing with dose, 1 ... Kµ µ≤ ≤ . The 
idea of the proposed design is to compute a Bayesian probability for each dose to be the target 
dose, that is, the probability for a dose to have the mean response close to the target η. The next 
assignment is made to the dose where this probability is the highest. We start with describing a 
Bayesian model for the data. We present the model for the case when outcome variances are 
assumed to be the same 2 2jσ σ= , j = 1,…, K. The case when the variances are not the same is 
easier, as data from each dose is handled separately.   
 Ignoring the monotonicity, a conjugate prior density (Gelman et al., 1995) can be 
specified as  
2 2
0 0| ~ ( , / )j j jN kµ σ µ σ ,  j = 1, 2,...,K, and 2 20 0~ ( , )IGσ ν σ , 
where IG denotes inverse gamma distribution. Let nj be the number of subjects assigned to ,jd  N 
= n1 +…+ nK. The posterior of 1( , ... , )Kµ µ ′=μ  conditional on 2σ  and observed responses y  is  
2| , ~ ( ; )j j jN M Vµ σ y , j = 1, 2,..., K, and 2 | ~ ( , )n nIGσ ν σy ,                     (1)                                           
where ),/()( 000 jjjjjjj nkynkM ++= µ  )/( 0
2
jjj nkV += σ , 0 / 2n Nν ν= + , and  
02 2
0 0
1 0
1 ( 1) ( )
2
K
j j
n j j j j
j j j
k n
n s y
k n
σ σ µ
=
  = + − + − 
+  
∑ , with 1( , ... , )Ky y ′  denoting the unrestricted 
maximum likelihood estimates of the mean response, and 2 21( ,..., )Ks s  denoting the empirical 
variances.  
To impose monotonic restriction on the posterior means 2| ,jµ σ y  we use the isotonic 
transformation approach of (Dunson and Neelon, 2003) and map unconstrained mean vector 
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1( , ... , )Kµ µ ′=μ  from 
KR → Ω  to obtain the posterior distribution for the restricted means. Here 
KRΩ ⊂  is defined by a set of vectors such that 1 ... Kµ µ≤ ≤ . We first compute the posterior 
distribution of unconstrained parameter vector μ , then obtain the draws from the posterior, and 
transform draws to the constrained draws from the posterior density for the constrained 
parameter vector, *μ , using the pool adjacent violators algorithm (PAVA) (Barlow et al., 1972). 
From transformed draws, for each dose dj, j = 1,…, K,  we compute the following probabilities 
2
2
2
( | , ),
( | , ),
( | , )
j j
j j
j j
P
P
P
π η ε µ η ε σ
ρ µ η σ
τ µ η σ
= − < < +
= >
= <
y
y
y
 
The probability jπ  shows how likely it is that dose dj is the target dose. The probability jρ  is 
the probability that the mean response at dj exceeds η . This probability is used to stop the trial if 
the lowest dose is too toxic in trials where toxicity related outcome is the main endpoint. 
Probabilities jρ  and jτ  are useful to decide whether a dose should be inserted as described in 
Section 4.2.2.  
 
4.2.2 The Bayesian design for continuous outcomes (BDCO) 
Subjects are assigned sequentially starting with the lowest dose. Similar to the start-up 
rule in toxicity dose-finding studies (Ivanova et al., 2003,Cheung, 2005), we recommend 
assigning at least three subjects to any untried dose before the dose can be escalated. Let k be the 
maximum dose with at least one subject assigned to it, and jn  be the number of subjects assigned 
to dose jd , j  = 1,…, k. The next subject is assigned to the dose with the maximum probability 
jπ . That is, the next subject is assigned to the dose dm that is most likely to be the target dose,  
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arg max jm π= . If the primary endpoint is a safety endpoint, the dose for the next subject is 
chosen only among the doses such that 0.95jρ < .  
Often, it takes several weeks to observe the outcome. As the first cohort of patients (often 
3 patients) at the higher previously untried dose are being followed, patients can be assigned at 
the lower dose. The BCDO allows incorporation of all data to find the best assignment for the 
next patient. For example, if values of response much higher than the target are observed at the 
dose level right below the dose where initial cohort is being treated, lower doses will be chosen 
for the next patient, as the next patient is assigned to the dose with the highest value of jπ . Other 
dose-finding designs, for example, the t-statistic design (Ivanova and Kim, 2009) and extended 
isotonic design (Chen et al., 2010) can be cumbersome to use with delayed outcome and rapid 
enrollment since the assignments are tied to the “current” dose. In our example, the “current” 
dose is the dose where the initial cohort of 3 is being treated, therefore next assignment is 
determined based on responses from these 3 patients. In design with a parsimonious working 
model the next assignment should be to the dose prescribed by the design, otherwise 
convergence is not guaranteed. Therefore, when patients are assigned at lower dose levels while 
the initial cohort of 3 is being followed at the higher dose, information from these additional 
patients should not be used to determine the next assignment.  If the primary endpoint is a safety 
endpoint, the trial is stopped earlier if 1 0.95ρ >  since the lowest dose is unsafe.  
 Bayesian framework allows setting up a rule to insert a dose similarly to trials with 
binary outcome (Hu et al., 2013). If the posterior mean *1µ  at the lowest dose is higher than the 
target, *1µ η> , and 1 0.95ρ > , a dose is inserted below d1. If 
*
Kµ η<  and 0.95τ >K   the dose is 
inserted above dK. Otherwise, we find two adjacent doses such that * * 1j jµ η µ +< < , then if 
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0.95jτ >  and 1 0.95jρ + >  a dose might be inserted between dj and dj+1. For example, in a trial 
with toxicity score endpoint and the target score of η = 0.28, 3 subjects were assigned to dose d1, 
12 subjects to d2 and 7 subjects to d3, yielding 1 0.07y = , 2 0.18y = , 3 0.40y = , 21 0.016s = , 
2
2 0.023s = , and 
2
3 0.006s = . With prior parameters 0 0jµ = , 0 0.1jk = , 0 0.05ν =  and 
0 0.0005σ = , and assuming equal variances, the order restricted posterior means at the three 
doses were *1ˆ 0.06µ = ,
*
2ˆ 0.16µ = , and 
*
3ˆ 0.39µ = . The probability that the mean at d2 is below the 
target was 2 0.99τ =  and the probability that the mean at d3 exceeds the target is 3 0.98ρ = . 
Therefore one should consider inserting a dose between d2 and d3.  
 
4.3 Example  
We use data from Friedman  et al. (1998) to illustrate the decision rules. The goal of the 
trial was to find a dose that produces undetectable AGT activity. Though the AGT outcome was 
continuous it was dichotomized at 10 fmol/mg to facilitate dose escalation in the trial. We use 
continuous outcome reported by Friedman et al. (1998). The trial accrued 30 patients; 3, 3, 13, 
and 11 patients to doses 40, 60, 80 and 100 mg/m2, respectively. We set the goal of the trial as to 
finding the dose with AGT activity equal to 5 fmol/mg protein. To construct our example (Table 
4.1) outcomes 31 32 33, ,y y y  were randomly selected from 13 outcomes reported at 80 mg/m
2, and 
we have randomly generated 3 outcomes at dose 120 mg/m2. The hypothetical trial was stopped 
when the data at the 100 mg/m2 dose-cohort were exhausted. Patients with undetectable AGT 
activity were assigned a value of 5 fmol/mg. Since the AGT activity was believed to be 
decreasing with dose, the dose was escalated if the mean AGT activity was higher than the target 
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5. Table 4.1 gives the averages and posterior means of AGT activity and decisions for each dose 
cohort.  
 
4.4 Simulation study 
For trials with continuous outcomes, we compared the new design with the t-statistic 
design ((Ivanova and Kim, 2009). In the t-statistics design, the t-statistic T for comparing the 
mean at the current dose with the target is computed. The next patient is assigned to the current 
dose if T−∆ < < ∆ , otherwise the dose is reduced or increased depending on the sign of T. Here 
Δ is a design parameter and Δ = 1 is recommended. We used the scenarios of true mean response 
as in (Ivanova and Kim, 2009) assuming the true variances are either equal or unequal across 
different doses. For each dose level dj, j = 1, 2, 3, 4, 5, 6, the outcome Yj has a normal 
distribution with mean 0.1j and variance 0.2. We also generated scenarios with unequal variances 
where Yj has mean 0.1j and variance 0.12j2. We varied the values of the target η , 0.1, 0.2, 0.3, 
0.4, 0.5, 0.6, so that the target dose is dose d1 in scenario 1, the target dose is d2 in scenario 2 etc. 
The sample size was 36 for all scenarios. Prior parameters were 0 0jµ = , 0 0.1jk = , 0 0.05ν =  and 
0 0.0005σ = . The BDCO parameter was set to 0.01ε = . The BDCO we simulated did not 
include the provision to insert doses. The BDCO was simulated when assuming equal variances 
and not making this assumption. The design performed slightly better when equal variances were 
assumed. Similarly both versions of the t-statistic design were simulated, under assumption of 
equal variances with and without this assumption. The t-statistic design performed slightly better 
when variances were not assumed to be equal. Therefore we only display results for the BDCO 
assuming equal variances and the t-statistic design assuming unequal variances. We obtain draws 
from the posterior density function described in Section 4.2.1 via Gibbs sampling algorithm and 
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then transform draws to the constrained draws from the posterior density of the constrained 
vector *μ . This process was performed 1500 times with the first 500 iterations discarded as 
burn-in. Results were obtained by simulations with 5000 replicates. 
Table 4.2 displays the proportion of runs where a dose was recommended as the target 
dose and the percentage of subjects allocated to each dose. As can be seen in Table 4.2, when the 
true variances are equal, the percent recommendations of correct dose are slightly higher for our 
new design than for the t-statistics design in five out of six scenarios. Whereas when the true 
variances are not equal, the percent recommendations of correct dose are about the same.  
 We also compared the performance of the new design in trials with toxicity score.  We 
used total toxicity profile score proposed by Ezzalfani et al. (2012) that can be obtained by 
converting various toxicity grades in three different toxicity types, renal, neurological and 
hematologic, into a single score. We used all 8 scenarios from Ezzalfani et al. (2012). The total 
sample size was 36 and the target score was 0.28. The designs compared were the t-statistics 
method ((Ivanova and Kim, 2009) and the Quasi-Likelihood Continual Reassessment Method 
QLCRM (Ezzalfani et al., 2012). The new design performed as good as the t-statistics design 
(Table 4.3), and QLCRM performed better than the new design and the t-statistic in several 
scenarios. Recall that compared to other methods, the new design is more flexible as dose 
assignments are not tied to the current dose. The new method allows both stopping the trial early 
and inserting doses. 
 We also investigated the robustness of the choice of design parameter ε . We rerun 
simulations with parameter ε   set to various values in (η /100, η /10) and obtained results very 
similar to results in Tables 4.2 and 4.3 (data are available from the authors).  
  
53 
 
4.5 Discussion 
We proposed a new Bayesian dose-finding design for continuous outcomes that is based 
on computing, for each dose, the probability that the mean response is close to the target value. 
Somewhat similar approach is a dose-finding design by Ji et al. (2010) for binary outcomes 
which is based on computing quantities similar to jπ , jτ  and jρ . However, the choice of 
assignments in the design of Ji et al. (2010) is tied to the current dose and a different strategy is 
used to determine the assignment based on the three quantities. Our new design allows making 
the best possible assignment for each incoming patient using all information available. For 
example, consider a trial where patients are assigned to the lower doses while the initial cohort of 
subjects is being followed at the higher dose. Since assignments are not tied to a current dose, 
information from both subjects at lower doses as well as subjects at a higher dose is used to make 
each new assignment.  
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Table 4.1 Example of a trial with subjects assigned in cohorts of 3. The target AGT activity is 5 
fmol/mg protein. Data were re-sampled from Friedman et al. (1998). 
 
Dose Data 
*,j jY µ  
Cohort 1, Dose 1   11 12 13( , , )y y y = (26.35, 42.00, 15.00) 27.78, 26.89 
Decision: Increase the dose, since *1 5µ >  
Cohort 2, Dose 2 21 22 23( , , )y y y = (23.00, 13.50, 10.83) 15.78, 15.20 
Decision: Increase the dose, since *2 5µ >  
 Cohort 3, Dose 3 31 32 33( , , )y y y = (11.70, 9.03, 5.00) 8.58, 8.12 
Decision: Increase the dose, since *3 5µ >  
Cohort 4, Dose 4  41 42 43( , , )y y y = (4.07, 5.00, 8.70) 5.92, 5.08 
Decision: Increase the dose, since *4 5µ >  
Cohort 5, Dose 5  51 52 53( , , )y y y = (2.01, 3.00, 4.10) 3.04, 2.56 
 While the first three subjects were followed at dose 5, three more subjects were enrolled 
at dose 4: 
Cohort 6, Dose 4 44 45 46( , , )y y y = (2.50, 4.07, 6.13)   5.08, 5.17 
Decision: Since *4 5µ >  and 
*
5 5µ < , compute 4 4Pr( 5) 0.040π µ= > =  and 
5 5Pr( 5) 0.020π µ= < = . Dose 4 has higher likelihood of being the target dose, therefore 
next assignment is to dose 4 
Cohort 7, Dose 4 47 48 49( , , )y y y = (3.60, 5.00, 5.00) 4.90, 4.95 
Decision: Since *3 5µ >  and 
*
4 5µ < , compute 3 0.020π =  and 4 0.050π = . Dose 4 has 
higher likelihood of being the target dose, therefore next assignment is to dose 4 
  4 10 4 11( , )y y = (6.80, 6.60) 5.22 
55 
 
Table 4.2 Proportion of trials where each dose was recommended as the target dose and 
proportion of subjects allocated to each dose by the t-statistics design and the new Bayesian 
design (BDCO). In case of unequal variances the variance of Yj is 0.12j2, {1,2,3,4,5,6}j ∈ , in 
case of equal variances the variance is 0.2. The target value in scenario k, k = 1,…, 6 is 0.1k. 
Results for the target dose are in bold. 
 
  TRUE Percent recommendation  Percent allocation 
  variance d1 d2 d3 d4 d5 d6  d1 d2 d3 d4 d5 d6 
Scenario 1   0.1 0.2 0.3 0.4 0.5 0.6              
t-statistics equal 0.93 0.07 0.00 0.00 0.00 0.00  0.82 0.17 0.01 0.00 0.00 0.00 
BDCO equal 0.91 0.10 0.00 0.00 0.00 0.00  0.78 0.21 0.02 0.00 0.00 0.00 
t-statistics unequal 0.97 0.03 0.00 0.00 0.00 0.00  0.82 0.17 0.01 0.00 0.00 0.00 
BDCO unequal 0.97 0.03 0.00 0.00 0.00 0.00  0.85 0.13 0.02 0.00 0.00 0.00 
Scenario 2   0.1 0.2 0.3 0.4 0.5 0.6             t-statistics equal 0.09 0.83 0.08 0.00 0.00 0.00  0.28 0.58 0.14 0.01 0.00 0.00 
BDCO equal 0.07 0.86 0.08 0.00 0.00 0.00  0.19 0.63 0.16 0.01 0.00 0.00 
t-statistics unequal 0.06 0.82 0.11 0.01 0.00 0.00  0.19 0.62 0.18 0.02 0.00 0.00 
BDCO unequal 0.04 0.84 0.11 0.01 0.00 0.00  0.16 0.63 0.17 0.03 0.00 0.00 
Scenario 3  0.1 0.2 0.3 0.4 0.5 0.6        t-statistics equal 0.00 0.09 0.82 0.10 0.00 0.00  0.10 0.26 0.51 0.12 0.01 0.00 
BDCO equal 0.00 0.07 0.83 0.09 0.00 0.00  0.09 0.19 0.55 0.16 0.01 0.00 
t-statistics unequal 0.00 0.14 0.67 0.17 0.02 0.00  0.09 0.26 0.48 0.15 0.02 0.00 
BDCO unequal 0.00 0.16 0.65 0.16 0.02 0.00  0.08 0.25 0.45 0.16 0.04 0.01 
Scenario 4   0.1 0.2 0.3 0.4 0.5 0.6              
t-statistics equal 0.00 0.00 0.10 0.80 0.11 0.00  0.09 0.10 0.25 0.45 0.11 0.01 
BDCO equal 0.00 0.00 0.08 0.81 0.11 0.00  0.08 0.09 0.18 0.49 0.15 0.02 
t-statistics unequal 0.00 0.00 0.25 0.55 0.17 0.03  0.08 0.11 0.32 0.36 0.11 0.02 
BDCO unequal 0.00 0.00 0.27 0.50 0.18 0.04  0.08 0.09 0.29 0.33 0.15 0.05 
Scenario 5   0.1 0.2 0.3 0.4 0.5 0.6              
t-statistics equal 0.00 0.00 0.00 0.12 0.77 0.11  0.08 0.09 0.10 0.24 0.39 0.10 
BDCO equal 0.00 0.00 0.00 0.09 0.80 0.11  0.08 0.08 0.09 0.17 0.43 0.15 
t-statistics unequal 0.00 0.00 0.02 0.36 0.45 0.18  0.08 0.09 0.16 0.32 0.25 0.10 
BDCO unequal 0.00 0.00 0.02 0.34 0.45 0.20  0.08 0.08 0.12 0.28 0.27 0.16 
Scenario 6  0.1 0.2 0.3 0.4 0.5 0.6 
       t-statistics equal 0.00 0.00 0.00 0.00 0.14 0.86  0.08 0.08 0.09 0.11 0.23 0.41 
BDCO equal 0.00 0.00 0.00 0.00 0.10 0.90  0.08 0.08 0.08 0.09 0.16 0.50 
t-statistics unequal 0.00 0.00 0.00 0.07 0.41 0.52  0.08 0.08 0.10 0.20 0.29 0.24 
BDCO unequal 0.00 0.00 0.00 0.07 0.40 0.54  0.08 0.08 0.09 0.15 0.26 0.33 
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Table 4.3 Proportion of trials where each dose was recommended as the target dose and 
proportion of subjects allocated to each dose by the QLCRM, the t-statistics design and the new 
Bayesian design (BDCO). The target is 0.28. Results at the target dose are in bold.    
 
                  Percent recommendation 
  
Percent allocation  
 d1 d2 d3 d4 d5 d6   d1 d2 d3 d4 d5 d6 
Scenario 1 0.18 0.28 0.36 0.41 0.43 0.44         
QLCRM 0.03 0.86 0.11 0.00 0.00 0.00   0.19 0.63 0.17 0.01 0.00 0.00 
t-statistics 0.06 0.85 0.10 0.00 0.00 0.00   0.26 0.60 0.14 0.00 0.00 0.00 
BDCO 0.04 0.86 0.09 0.00 0.00 0.00   0.22 0.60 0.15 0.02 0.00 0.00 
Scenario 2 0.10 0.20 0.31 0.39 0.44 0.48         
QLCRM 0.00 0.13 0.85 0.02 0.00 0.00   0.09 0.21 0.61 0.09 0.00 0.00 
t-statistics 0.00 0.18 0.80 0.01 0.00 0.00   0.10 0.35 0.50 0.05 0.00 0.00 
BDCO 0.00 0.22 0.77 0.01 0.00 0.00   0.10 0.36 0.46 0.07 0.00 0.00 
Scenario 3 0.11 0.18 0.28 0.36 0.41 0.43         
QLCRM 0.00 0.03 0.84 0.13 0.00 0.00   0.09 0.15 0.57 0.18 0.01 0.00 
t-statistics 0.00 0.06 0.83 0.11 0.00 0.00   0.10 0.25 0.52 0.12 0.00 0.00 
BDCO 0.00 0.06 0.83 0.10 0.00 0.00   0.10 0.22 0.52 0.15 0.02 0.00 
Scenario 4 0.05 0.12 0.27 0.37 0.40 0.46         
QLCRM 0.00 0.00 0.83 0.17 0.00 0.00   0.08 0.09 0.51 0.30 0.01 0.00 
t-statistics 0.00 0.00 0.93 0.07 0.00 0.00   0.08 0.16 0.60 0.16 0.00 0.00 
BDCO 0.00 0.00 0.92 0.07 0.00 0.00   0.08 0.17 0.60 0.13 0.01 0.00 
Scenario 5 0.05 0.10 0.19 0.31 0.42 0.45         
QLCRM 0.00 0.00 0.09 0.91 0.01 0.00   0.08 0.08 0.15 0.60 0.08 0.00 
t-statistics 0.00 0.00 0.15 0.84 0.00 0.00   0.08 0.09 0.32 0.45 0.04 0.00 
BDCO 0.00 0.00 0.14 0.86 0.00 0.00   0.08 0.10 0.32 0.44 0.06 0.00 
Scenario 6 0.05 0.11 0.18 0.28 0.36 0.41         
QLCRM 0.00 0.00 0.03 0.81 0.17 0.00   0.08 0.09 0.13 0.51 0.19 0.01 
t-statistics 0.00 0.00 0.07 0.82 0.11 0.00   0.08 0.10 0.24 0.46 0.11 0.00 
BDCO 0.00 0.00 0.08 0.82 0.10 0.00   0.08 0.10 0.22 0.45 0.14 0.02 
Scenario 7 0.04 0.05 0.11 0.18 0.28 0.36         
QLCRM 0.00 0.00 0.00 0.03 0.80 0.18   0.08 0.08 0.08 0.12 0.45 0.18 
t-statistics 0.00 0.00 0.00 0.08 0.79 0.13   0.08 0.09 0.10 0.23 0.40 0.10 
BDCO 0.00 0.00 0.00 0.10 0.80 0.10   0.08 0.08 0.10 0.21 0.39 0.13 
Scenario 8 0.05 0.11 0.14 0.19 0.25 0.35         
QLCRM 0.00 0.00 0.00 0.02 0.83 0.16   0.08 0.08 0.09 0.15 0.48 0.12 
t-statistics 0.00 0.00 0.00 0.01 0.78 0.21   0.08 0.09 0.10 0.16 0.40 0.17 
BDCO 0.00 0.00 0.00 0.01 0.80 0.19   0.08 0.08 0.09 0.13 0.44 0.18 
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CHAPTER 5 
USE OF SELECTIVE PHENOTYPYING TO INCREASE POWER OF GENETIC 
ASSOCIATION STUDIES 
 
 
5.1 Introduction 
Replication studies play an important role in validating results from a GWAS. For many 
GWASs, the trait being studied is a quantitative measure that required a significant investment of 
time and money to collect.  There are many potential replication cohorts that have existing 
genotype data on candidate SNPs under study but who have yet to measure the quantitative trait 
of interest.  For these studies, the number of subjects that can be measured for the quantitative 
trait could be limited by time and cost constraints. The selection of the subset of subjects to 
phenotype would likely play a critical role in the success or failure of the replication study.  
Historically, the expense of genotyping has been the major cost constraint for large-scale 
genetic association studies. One solution to remedying the high cost of genotyping, when 
studying quantitative traits, was to preferentially select subjects with extreme values of the 
phenotype of interest for genotyping (Darvasi and Soller, 1992).   Today, many large cohort 
studies have existing genome-wide SNP data and the burden of expense has now shifted to 
unmeasured phenotypes.  
Methods to maximize power using selective phenotyping have been developed for 
experimental animal and plant crosses. These methods can be classified into two categories. One 
category was developed to maximize the number of recombination events in selected subjects in 
order to have increased power to narrow the location of the unknown underlying causal locus 
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amongst tested genetic markers in a linkage map. The subject with the largest number of 
recombination events between all markers is selected first, and so on, until the number of 
subjects is equal to the final allowable sample size (Jannink, 2005, Xu et al., 2005).  The other 
category of methods focuses on balancing the distribution of alleles for the selected sets of 
markers. In this category, measures of similarity are used to find the subset of subjects with 
genotypes as dissimilar as possible (Sen et al., 2009, Jin et al., 2004). A more recent Bayesian 
approach combines some of the features of both approaches (Gagneur et al., 2011).  Though 
there are obvious differences between these methods, the rationale behind the methods is similar. 
Namely, the goal is to identify the subset of subjects who are as genetically diverse as possible 
with respect to distributions of recombination events and/or marker genotype data.  
Determining an optimal selective phenotyping strategy for human genetic association 
studies of multiple variants is challenging.  Assuming an additive genetic risk model, 
maximizing power for a single SNP associated with a quantitative phenotype is achieved by 
phenotyping an equal number of subjects who are homozygous for the major and minor alleles. 
Identifying the optimal selection strategy when considering multiple SNPs is much more 
difficult, as such a strategy has to consider a possible wide-range of allele frequencies and effect 
sizes across the SNPs being studied. The power for a subset of SNPs of interest might not be 
sensitive to sample selection while the power for the remaining SNPs could be very sensitive to 
sample selection. The selection of subjects for phenotyping that maximizes power across a set of 
SNPs is ultimately a complex optimization problem. 
Simulated annealing (SA) is a computationally efficient optimization algorithm that finds 
the global minimum or maximum of complex functions containing many variables (Kirkpatrick 
et al., 1983, Coghlan et al., 2001). SA originated from the Metropolis’s Algorithm (Metropolis et 
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al., 1953). In contrast to other optimization algorithms, SA does not require calculation of 
derivatives. The method is motivated by an analogy to solving the combinatorial optimization 
problem related to the physical annealing process of heating solids to a high temperature, so that 
the atoms will be able to rearrange freely, followed by a slow cooling process that results in a 
strong crystal in the minimum energy configuration.  
We describe a method, based on SA, which identifies the optimal subset of subjects, 
based on their available genotype data at a set of SNPs of interest, to be phenotyped for inclusion 
in a genetic association study.  The samples are chosen to either maximize average or minimum 
power across the selected SNPs.  We demonstrate, through simulations and an empirical 
example, the improved power that can be achieved by using this approach compared to the 
alternative approach of selecting a random sample for phenotyping. 
 
5.2 Methods 
5.2.1 Statistical power calculation 
We follow the approach described by Ambrosius et al. to calculate statistical power for a 
SNP associated with a quantitative trait (Ambrosius et al., 2004). Specifically, we utilized a 
linear regression model to study the association between the phenotype and SNP  (i.e.,Model : 
y=Xβ + ε, where y is the vector containing the dependent continuous variable for phenotype; X 
is the matrix of independent variables written as X=[1 g], g being the vector of independent 
variables for the genotype; β is the vector of regression coefficients written as β=[β0, β1]T such 
that β0 is the parameter for the intercept and β1 is the coefficient explaining the effect of 
genotype; ε is a vector of independent and normally distributed random variable with mean zero 
and variance σ2).  In genetic association models, we test the null hypothesis (H0) that no 
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association exists between the phenotype and genotype (i.e., H0: β1=0). This hypothesis can be 
tested using an F-test. To calculate the power under the alternative hypothesis (H1) that there is 
an association between phenotype and genotype  (i.e., H1: β1≠0), we need to specify the critical 
value (crit) used to assess significance and the value of the non-centrality parameter, φ.   The 
critical value is calculated under the null hypothesis satisfying Pr[Fdf1,fdf2 > Fcrit]=α. Assuming an 
additive effects model for genotype on phenotype, we calculate power, Pr[Fdf1, fdf2,φ > Fcrit], as 
follows (Ambrosius et al., 2004). 
Pow =Pr[Fdf1,df2, ϕ  > Fcrit],  where: 2' ' / (2 )Z Zϕ β β σ= , 
the non-centrality parameter for the F distribution 
2 2 22 3 1 3 1 2
1 2 3
2 2' ( ) ( ) ( )k k k k k kZ Z k k k
k k k
+ − +
= + +  
 k=k1+k2+k3, df1=1,df2=k-2 
 k1 is number of subjects with genotype AA; 
 k2 is number of subjects with genotype AB; 
 k3 is number of subjects with genotype BB; 
 2σ is the within group variance.  
 
5.2.2 Simulated Annealing Algorithms 
Our goal is to find the subsample, of fixed size, of subjects from the complete sample that 
provides the greatest overall average power across all SNPs of interest.  Constructing and 
calculating average power for all possible subsamples is intractable.  Simulated annealing, a 
Monte Carlo algorithm designed to mimic the heating and subsequent cooling of a substance into 
a solid state which minimizes the overall kinetic energy, is a widely used algorithm for 
minimization/maximization problems (Kirkpatrick et al., 1983, Borneman et al., 2001).  
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Below is the detail of simulated annealing algorithm used in our study: 
Parameters include the function to be optimized (here average power), the initial 
temperature (t0), the rate of cooling (α ) and the convergence criteria (ε ). 
Let K be total number of available subjects for phenotyping and k (< K) be the number of 
subjects that will be phenotyped. Let n be the number of candidate SNPs that will be tested for 
association. Let Si ={sj}, where {sj} is a set of k subjects, without replacement, from the 
complete sample S at iteration i. Let Si+1 = Si –sa + sb, where subject a is randomly selected and 
removed from Si and subject b is randomly selected from S/Si and added to Si+1. Let Pow(Si) and 
Pow(Si+1) = average power across n SNPs for set of subjects Si and Si+1, respectively. To 
calculate average power, we calculate the power for each individual selected SNP, sum up the 
powers and divide by the total number of selected SNPs.  
Iterative approach: 
1) Start with S0 and calculate Pow(S0) (i=0).  
2) Create S1 (i=1) by randomly dropping one subject out from S0 and randomly adding 
one subject from S/S0. 
3) Calculate Pow(S1). 
4) If Pow(S1) > Pow(S0), choose in favor of sample S1 as new “best” sample. Else, with 
probability = exp((Pow(S1)- Pow(S0))/t0), existing sample S1 is replaced by S0. (i.e. 
always accept a favorable move and some times, with decreasing probability as the 
system cools, choose the less favorable sample.) 
5) t1 =α  × t0, where t0 is initial starting temperature and α = user defined constant 
cooling rate. 
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6) Continue iteratively, creating sample Si+1 from Si in similar fashion and 
calculating power for sample Si+1.  
7) If Pow(Si+1) > Pow(Si), choose in favor of sample Si+1 as new “best” sample. 
Else, with probability = exp((Pow(Si+1)- Pow(Si))/ti), existing sample Si+1 is replaced by 
Si and carried forward to the next iteration.  
8) ti = α  × ti-1 
9) Continue until ti < ε , where ε  is a user-defined threshold for convergence. 
Final sample at last iteration is chosen as optimal sample. 
The algorithm was programmed in R (version 2.11.0; www.r-project.org). 
 
5.2.3 Data simulation 
We simulated two sample pools of size K=10,000, each with a different number of target 
SNPs (n=8 [minor allele frequency (MAF) = 0.05 (x2 SNPs), 0.1 (x2), 0.2, 0.3, 0.4, 0.5]; n=80 
[MAF=0.05 (x20), 0.1 (x20), 0.2 (x10), 0.3 (x10), 0.4 (x10), 0.5 (x10)]). For each constructed 
SNP dataset, SNP genotype data were generated randomly, from their respective MAFs, 
assuming they were independent from other SNPs and followed Hardy-Weinberg equilibrium. 
For each sample design, we then calculated power under two scenarios: 1) assuming a constant 
mean effect (fixed β  or change in mean per variant allele) and 2) assuming a constant 
proportion of total variation explained (fixed R2) by each SNP. We assumed that σ2 = 1 in all 
power calculations and used a Bonferroni significance threshold of α=0.00625 (0.05/8) and 
α=0.000625 (0.05/80) for the models with 8 and 80 SNPs, respectively. Only 2000 subjects were 
assumed to be available for phenotyping; genotype data were assumed to be complete and 
available on all subjects prior to phenotype sample selection. For each alternative model we 
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selected 100 random samples of 2000 subjects.  The average power across all SNPs, and the 
individual power for each SNP, was calculated for each random sample. These same 100 random 
samples were then used as initial starting values in our simulated annealing algorithm to identify 
a sample of 2000 subjects that maximized the average power across all selected SNPs. The 
detailed information about the alternative models are shown in Table 5.1.  The parameters used 
for the simulated annealing algorithm were as follows:  t0=400, α =0.9999, ε=0.000001.  
 
5.2.4 Replication of C Reactive Protein (CRP) associations in the Jackson Heart Study 
(JHS) 
 
To assess the utility of our approach in a “real data” replication study, we used genotype 
data from JHS to attempt to confirm a reported association from the Women’s Health Initiative 
(WHI) between five independent genetic variants and CRP. Reiner et al. (Reiner et al., 2012) 
recently reported five genetic variants to be significantly associated with CRP levels in African 
Americans. JHS, a longitudinal population-based cohort from Jackson, Mississippi, represents 
the largest single-site, prospective, epidemiological investigation of cardiovascular disease in 
African Americans (Sempos et al., 1999). Genotype data, generated from the Affymetrix 6.0 
Array, on 2983 JHS subjects with CRP data were available to be included in a replication study 
of the Reiner et al. findings. Three reported SNPs (rs1160985, rs6734238, and rs7748513) were 
directly available on JHS subjects from the Affymetrix array.  Two proxy SNPs were used for 
the reported SNPs rs16827466 and rs797943. The selected proxy SNP for rs16827466 was 
rs12239267 (r2=0.945 and D'=1.00). The selected proxy SNP for rs797943 was rs2393791 
(r2=0.558 and D'=1.00). We first attempted to replicate the previous findings using the entire JHS 
sample. CRP was log-transformed to meet distributional assumptions and extreme values of 
CRP>100, likely representing acute infections were removed. Linear regression models were 
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performed, regressing log-CRP on each SNP individually with covariate adjustment for BMI, 
sex, age, smoking status (yes/no) and the first four principal components used to control for 
population stratification.  
We next considered the scenario where we could have only afforded to have phenotyped 
500 subjects. For each SNP, we randomly sampled 100 different samples, without replacement, 
performed the same linear models as for the complete data and calculated, across these 100 
random samples, the mean p-value, the standard deviation of the p-values, and the proportion of 
samples where the SNP tests (p-value < 0.05) would have rejected the null hypothesis and 
confirmed the previous results. We next used so same random samples as initial samples in our 
simulated annealing algorithm to identify the, a priori, optimal sample for phenotyping and 
repeated the linear model analyses performed for the random samples.  The alternative models 
for each SNP used in the simulated annealing algorithm were defined by the observed effect size 
estimates in the original report.  
 
5.3 Results 
5.3.1 Simulations 
Results for the simulation analyses are presented in Tables 5.2 and 5.3.  For Model 1, we 
assumed all SNPs, regardless of MAF, explained the same proportion of variation of the 
quantitative phenotype (Table 5.2).  As expected, for random samples mean power was near 
uniform across MAFs for both the 8 (average mean power~0.67 for Model 1A) and 80 (average 
mean power ~0.68 for Model 1B) SNP models. Gains in mean power were observed for all 
SNPs, regardless of MAF, with application of the simulated annealing algorithm. The largest 
gains were observed for the SNPs with lower MAF and bigger gains in mean power were 
65 
 
observed for the 8 SNP model compared to the 80 SNP model. For the models with constant 
main effect (Models 2A and 2B; Table 5.3), not surprisingly SNPs with lower MAF had less 
mean power than SNPs with higher MAF for the random samples. While this pattern remained 
true for samples selected from the simulated annealing algorithm, big gains in power were 
especially noted for SNPs with low MAF. Once again, bigger gains in power for the simulated 
annealing approach were observed for the model with 8 candidate SNPs compared to the model 
with 80 candidate SNPs.  
In addition to higher mean power estimates when using our simulated annealing approach 
to selective phenotyping, we note that there is considerably more variability of the power 
estimates for random samples compared to the simulated annealing selected phenotype samples 
that used the same random samples as initial samples (Tables 5.2 and 5.3).  As illustrated in 
Figure 5.1 for Model 1A, the mean power for the simulated annealing approach converged 
quickly to similar values irrespective of the initial starting sample.  
 
5.3.2 JHS CRP replication study 
The reported association with CRP in WHI was replicated (p<0.05) for four out of five 
SNPs using the complete sample in JHS (Table 5.4). Restricting the JHS sample size to random 
draws of size n=500 considerably reduced the evidence for replication in JHS.  Focusing on the 
four SNPs with evidence for association in the complete sample, only rs12239267, a proxy for 
WHI SNP rs16827466, was consistently replicated in the random draws (mean p-value = 0.014; 
96% of draws replicated the result) (Table 5.5). While rs1160985 was replicated in 65% of the 
random draws, the mean p-value was only 0.12. The remaining two SNPs consistently 
demonstrated little evidence for association.  Applying our selective phenotyping approach 
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resulted in much higher probabilities to replicate the WHI findings. Specifically, 100% of the 
selective phenotype samples replicated the findings at rs12239267 and rs1160985, while 86% of 
the time the result at rs6734238 was also replicated. In addition, the mean p-values were 
substantially smaller for these SNPs using the selective phenotyping method compared to using 
random samples. Little evidence for association was observed for rs2393791, a proxy for WHI 
SNP rs797943, using either approach. 
 
5.4 Discussion 
Replication studies are important for controlling the type I error rate of GWAS 
discoveries.  GWASs have identified many associations for quantitative measures and often 
these measures are missing in potential replication studies.  We describe a method that provides 
investigators, who are concerned about the costs of measuring these quantitative outcomes, an 
approach to select an a priori optimal subsample of their data for phenotyping when conducting 
a replication study. 
 Simulated annealing is a popular optimization algorithm for complex functions. Here we 
describe the function as the average power across a selected set of SNPs. Simulated annealing 
has been used in solving optimization problems such as probe selection (Borneman et al., 2001) 
and optimal bit-pattern representation of amino acids (Coghlan et al., 2001).  The algorithm itself 
is very flexible and other functions could be readily adapted. For example, an investigator might 
be interested in finding the subsample that maximizes the minimum power of a SNP among a set 
of SNPs. In addition, features such as constraints or weights could be easily included so that 
some SNPs, deemed more critical to the experiment, get more weight in the selection scheme. As 
with any simulated annealing design, care by the user should be applied when selecting variables 
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such as starting temperature, cooling rate and convergence criteria.  As we applied in Figure 5.1, 
a plot of the current value of the power function across iteration is a useful guide to assess 
convergence properties. 
 We show through simulations and an empirical example the increase in power our 
approach can have relative to random sampling.  It was not surprising that the biggest gains were 
observed for SNPs with lower MAF and that the gains were stronger for the smaller the set of 
SNPs being considered. Replication studies with a narrower set of SNPs to follow will gain more 
than studies with a more exhaustive set of variants to follow.  For studies that want to initially 
focus on replication but then subsequently contribute to future discovery on a broader list of 
SNPs, the selection strategy should have little impact, relative to random sampling, on the power 
for SNPs not included among, and not in linkage disequilibrium with, the list of SNPs used for 
optimization. There is like little risk the method would harm power for non-selected SNPs.  Like 
any power calculation, the method relies on user specified effect estimates, under the alternative 
hypothesis, for individual SNPs.  Often these estimates can be obtained from the discovery 
study, though some caution is advised, especially for less common variants, that these initial 
effect estimates are often biased (too strong). This phenomenon has been described as “the 
winner’s curse” (Bush and Moore, 2012).  We have performed additional simulations (data not 
shown) that suggest the method is reasonably robust to model misspecification, either due to 
inflated effect estimates for a subset of selected SNPs or the inclusion of null SNPs.  
 Herein, we describe the method of optimal phenotype selection for replication studies, 
where the set of genotyped variants for follow up, and their associated effect size estimates, are 
relatively easy to define based on the preceding discovery study.  The method should also be 
considered for candidate gene studies, where the list of SNPs to include is typically modest. 
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Under this scenario, the effect size estimates may not be available from previous studies; thus the 
choice of effect size estimates, similar to standard single SNP power analyses, are more 
arbitrary.  Still, reasonably informed choices can be made based on plausibility (including 
information on heritability, MAF, etc.) and results from other studies.  We are currently working 
on adapting the method for gene-based tests of less common variants (relatively straight forward 
for many “gene-burden” statistics) and multi-stage GWAS studies, where a random sample is 
selected in stage 1 and an informed, phenotype selected, sample is selected in stage 2. Finally, it 
is possible to extend the method to include imputed genotype data. Given the relative low 
expense of genotyping a small number of variants compared to measuring a new phenotype, 
many investigators will choose to directly genotype the SNPs in a replication study. Other 
burdens besides cost might limit the ability to perform additional genotyping and thus the 
consideration of using imputed genotype data is an important one. 
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Table 5.1 Four models used for simulations 
 
   MODEL 1A: Constant R2 for 8 SNPs 
   SNP MAF 
 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) 
β 0.229 0.167 0.125 0.109 0.102 0.100 
R2 0.005 0.005 0.005 0.005 0.005 0.005 
MODEL 1B: Constant R2 for 80 SNPs 
   SNP MAF 
 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) 
β 0.281 0.204 0.153 0.134 0.125 0.123 
R2 0.0075 0.0075 0.0075 0.0075 0.0075 0.0075 
MODEL 2A: Constant β for 8 SNPs 
    SNP MAF 
 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) 
β 0.125 0.125 0.125 0.125 0.125 0.125 
R2 0.0015 0.0028 0.005 0.0066 0.0075 0.0078 
MODEL 2B: Constant β for 80 SNPs 
   SNP MAF 
 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) 
β 0.153 0.153 0.153 0.153 0.153 0.153 
R2 0.0022 0.0042 0.0075 0.0098 0.0113 0.0117 
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Table 5.2 Mean Power (SD) with constant R2 
 
Model 1A (8  SNPs, R2=0.005, α=0.00625): 
Random Sample (100 draws of 2000/10,000 samples) 
SNP MAF 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) Avg(n=8) 
0.679 0.663 0.656 0.667 0.666 0.667 0.67 
(0.016) (0.015) (0.022) (0.014) (0.009) (0.011) (0.01) 
Simulated Annealing Selected Sample (100 SA runs of 2000/10,000 samples) 
SNP MAF 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) Avg(n=8) 
0.971 0.941 0.93 0.915 0.894 0.887 0.93 
(0.000) (0.000) (0.001) (0.001) (0.001) (0.001) (0.00) 
Model 1B (80  SNPs, R2=0.0075, α=0.000625): 
Random Sample (100 draws of 2000/10,000 samples) 
SNP MAF 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) Avg(n=80) 
0.674 0.668 0.679 0.678 0.678 0.679 0.68 
(0.011) (0.006) (0.009) (0.004) (0.004) (0.003) (0.00) 
Simulated Annealing Selected Sample (100 SA runs of 2000/10,000 samples) 
SNP MAF 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) Avg(n=80) 
0.918 0.862 0.812 0.776 0.761 0.761 0.83 
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.00) 
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Table 5.3 Mean Power (SD) with constant β   
 
Model 2A (8  SNPs, β=0.125, α=0.00625) 
Random Sample (100 draws of 2000/10,000 samples) 
SNP MAF 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) Avg(n=8) 
0.155 0.351 0.655 0.811 0.876 0.889 0.53 
(0.011) (0.01) (0.022) (0.016) (0.006) (0.006) (0.01) 
Simulated Annealing Selected Sample 
SNP MAF 
0.05(n=2) 0.1(n=2) 0.2(n=1) 0.3(n=1) 0.4(n=1) 0.5(n=1) Avg(n=8) 
0.519 0.698 0.929 0.953 0.959 0.961 0.78 
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.00) 
Model 2B (80  SNPs, β=0.153, α=0.000625) 
Random Sample (100 draws of 2000/10,000 samples) 
SNP MAF 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) Avg(n=80) 
0.094 0.301 0.673 0.851 0.912 0.926 0.52 
(0.011) (0.010) (0.022) (0.016) (0.006) (0.006) (0.01) 
Simulated Annealing Selected Sample 
SNP MAF 
0.05(n=20) 0.1(n=20) 0.2(n=10) 0.3(n=10) 0.4(n=10) 0.5(n=10) Avg(n=80) 
0.208 0.535 0.808 0.899 0.932 0.945 0.63 
(0.001) (0.001) (0.001) (0.001) (0.001) (0.001) (0.00) 
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Figure 5.1 Rapid Convergence of Simulated Annealing Algorithm Irrespective of Starting 
Sample 
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Table 5.4 Results for full sample (N=2983) 
 
Variant Chr Position MAF Beta (β) Se p-value 
rs1160985 19q13 50,095,252 0.37 -0.14 0.03 1.2×10-6 
rs12239267 1p13 159,670,928 0.04 0.35 0.04 2.4×10-22 
rs2393791 12p13 121,423,956 0.39 -0.058 0.03 0.039 
rs6734238 2q13 113,557,501 0.47 0.072 0.03 0.0067  
rs7748513 6p21 41,235,950 0.42 0.015 0.03 0.57 
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Table 5.5 Evidence for replication in JHS using random and selective phenotyping (100 
samples, N=500)  
 
Variant 
Random  sample Simulated annealing  sample 
Mean p-value 
(std dev) 
Proportion 
p<0.05 
Mean p-value 
(std dev) 
Proportion 
p<0.05 
rs1160985 0.12 0.65 0.0081 1.00 
(0.18) (0.0068) 
rs12239267 0.014 0.96 3.5×10-5 1.00 
(0.066) (7.0×10-5) 
rs2393791 0.48 0.17 0.57 0.00 
(0.3) (0.27) 
rs6734238 0.32 0.17 0.023 0.86 
(0.28) (0.026) 
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